[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 263
1. Torlakovic E, Lilleby W, Berner A, Torlakovic G, Chibbar R, Furre T, Fosså SD: Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma. Int J Cancer; 2005 Nov 10;117(3):381-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression, distribution and the role of steroid receptors in benign and malignant untreated prostate tissues is well recognized, however, the status of steroid receptors in prostate after radiotherapy (RT) for adenocarcinoma has not yet been studied fully.
  • Significantly higher level of ER-beta expression was found in post-radiation samples of prostate adenocarcinoma and benign epithelium.
  • Tumor AR expression did not change significantly.
  • High levels of pretreatment tumor ER-beta were associated with local recurrence after RT and decreased biochemical recurrence-free survival (p = 0.028).
  • Upregulation of all steroid receptors in the prostate stroma and upregulation of ER-beta in the tumor epithelium after RT, may represent a protective tissue response to radiation-induced tissue injury.
  • Although stromal AR was doubled after RT, the tumor and benign epithelium expression of AR seemed resistant to change by RT.
  • [MeSH-minor] Biopsy, Needle. Cell Line, Tumor. Epithelial Cells / pathology. Humans. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15900599.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Steroid
  •  go-up   go-down


2. Richter M, Meyer W, Küster J, Middel P: Exophytic benign mixed epithelial stromal tumour of the kidney: case report of a rare tumour entity. Diagn Pathol; 2010;5:16
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exophytic benign mixed epithelial stromal tumour of the kidney: case report of a rare tumour entity.
  • BACKGROUND: Mixed epithelial and stromal tumour (MEST) represents a recently described benign composite neoplasm of the kidney, which predominantly affects perimenopausal females.
  • Most tumours are benign, although rare malignant cases have been observed.
  • Surgical exploration showed a tumour arising from the lower anterior hilus of the left kidney.
  • The tumour could be excised by preserving the kidney.
  • By intraoperative frozen section the tumour showed characteristic features of MEST with epithelial-covered cysts embedded in an "ovarian-like" stroma.
  • Additional immunohistochemistry investigations showed expression for hormone receptors by the stromal component of the tumour.
  • Commonly, the tumour arises from the renal parenchyma or pelvis.
  • The tumour is composed of an admixture of cystic and sometimes more solid areas.
  • CONCLUSION: MEST represents a distinctive benign tumour entity of the kidney, which affects perimenopausal woman.
  • The tumour should be distinguished from other cystic renal neoplasms.
  • By imaging studies it is difficult to distinguish between a benign or malignant nature of the tumour.
  • [MeSH-major] Epithelial Cells / pathology. Kidney Neoplasms / pathology. Mixed Tumor, Malignant / pathology. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ultrastruct Pathol. 2005 May-Aug;29(3-4):283-6 [16036882.001]
  • [Cites] Lancet Oncol. 2004 Dec;5(12):747-9 [15581546.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):489-500 [17414095.001]
  • [Cites] Pathology. 2007 Apr;39(2):235-40 [17454754.001]
  • [Cites] Mod Pathol. 2008 Jan;21(1):60-5 [17873894.001]
  • [Cites] Urology. 2008 Jun;71(6):1142-8 [18313107.001]
  • [Cites] Eur Urol. 2008 Dec;54(6):1237-46 [18006141.001]
  • [Cites] Eur Urol. 2008 Dec;54(6):1245-6 [18006142.001]
  • [Cites] Am J Surg Pathol. 2009 Jan;33(1):72-80 [18971776.001]
  • [Cites] APMIS. 2008 Nov;116(11):1013-5 [19133001.001]
  • [Cites] Pathology. 2009;41(4):403-6 [19404861.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):958-70 [10895818.001]
  • [Cites] J Urol. 2001 Oct;166(4):1381-2 [11547080.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):700-2 [11764393.001]
  • [Cites] Histopathology. 2004 Mar;44(3):302-4 [14987239.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):359-67 [15322873.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):2-20 [9503503.001]
  • [Cites] Pathol Res Pract. 1998;194(6):445-8 [9689654.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jan;130(1):80-5 [16390243.001]
  • (PMID = 20193076.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2842239
  • [General-notes] NLM/ Original DateCompleted: 20100609
  •  go-up   go-down


3. Monica B, Larosa M, Facchini F, Pozzoli G, Franceschetti I, Piscioli I: Low grade epithelial stromal tumour of the seminal vesicle. World J Surg Oncol; 2008;6:101

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low grade epithelial stromal tumour of the seminal vesicle.
  • BACKGROUND: The mixed epithelial stromal tumour is morphologically characterised by a mixture of solid and cystic areas consisting of a biphasic proliferation of glands admixed with solid areas of spindle cells with variable cellularity and growth patterns.
  • In previous reports the seminal vesicle cystoadenoma was either considered a synonym of or misdiagnosed as mixed epithelial stromal tumour.
  • The recent World Health Organisation Classification of Tumours considered the two lesions as two distinct neoplasms.
  • This work is aimed to present the low-grade epithelial stromal tumour case and the review of the literature to the extent of establishing the true frequency of the neoplasm.
  • CASE PRESENTATION: We describe a low-grade epithelial stromal tumour of the seminal vesicle in a 50-year-old man.
  • The histology revealed biphasic proliferation of benign glands admixed with stromal cellularity, with focal atypia.
  • CONCLUSION: Cystoadenoma and mixed epithelial stromal tumour of seminal vesicle are two distinct pathological entities with different histological features and clinical outcome.
  • Due to the unavailability of accurate prognostic parameters, the prediction of the potential biological evolution of mixed epithelial stromal tumour is still difficult.
  • In our case magnetic resonance imaging was able to avoid an exploratory laparotomy and to establish an accurate conservative surgical treatment of the tumour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 2001 Aug;33(3):399-402 [11523949.001]
  • [Cites] Am J Surg Pathol. 1987 Mar;11(3):210-7 [3030148.001]
  • [Cites] Arch Ital Urol Androl. 2003 Sep;75(3):164-5 [14661396.001]
  • [Cites] J Urol. 1974 Jun;111(6):808-9 [4857471.001]
  • [Cites] Scand J Urol Nephrol. 1984;18(4):341-2 [6390669.001]
  • [Cites] Pathol Int. 2004 Dec;54(12):924-9 [15598315.001]
  • [Cites] N Y State J Med. 1987 Jan;87(1):48-9 [3470649.001]
  • [Cites] J R Soc Med. 1988 May;81(5):294-5 [3385715.001]
  • [Cites] Indian J Pathol Microbiol. 1989 Oct;32(4):314-5 [2698864.001]
  • [Cites] Int J Urol. 2006 Aug;13(8):1138-40 [16903949.001]
  • [Cites] J Urol. 1992 Jun;147(6):1621-4 [1593703.001]
  • [Cites] Arch Pathol Lab Med. 1992 Oct;116(10):1072-6 [1329693.001]
  • [Cites] Cancer. 1993 Mar 15;71(6):2055-61 [8382998.001]
  • [Cites] Abdom Imaging. 1993;18(3):298-300 [8508100.001]
  • [Cites] Urology. 1998 May;51(5):840-5 [9610606.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1951 Oct 24;26(22):406-14 [14883202.001]
  • [Cites] Int J Urol. 2006 May;13(5):640-2 [16771745.001]
  • [Cites] Int J Urol. 2002 Oct;9(10):599-601 [12445241.001]
  • (PMID = 18811925.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2564931
  •  go-up   go-down


Advertisement
4. Stojsić J, Milenković B, Radojicić J, Percinkovski M: [Alveolar adenoma -- a rare lung tumour]. Srp Arh Celok Lek; 2007 Jul-Aug;135(7-8):461-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Alveolar adenoma -- a rare lung tumour].
  • INTRODUCTION: Alveolar adenoma belongs to the group of benign epithelial tumours.
  • CONCLUSION: Alveolar adenoma is a rare benign lung tumour, most frequently presented as a solitary pulmonary nodule.
  • After complete surgery, the tumour neither relapses nor malignantly alters.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17929540.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


5. Yang HJ, Yang KC: A new method for facial epidermoid cyst removal with minimal incision. J Eur Acad Dermatol Venereol; 2009 Aug;23(8):887-90
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Facial epidermoid cyst is a common benign epithelial tumour frequently seen in young or middle-aged people and may cause aesthetic disability.
  • The skin above the epidermoid cysts was infiltrated with local 0.1-cc 1% xylocaine anaesthetic by using a 26-gauge needle first, then 3-mm incisions were made with a No.11 surgical blade.
  • [MeSH-major] Epidermal Cyst / surgery. Minimally Invasive Surgical Procedures / methods. Skin Diseases / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19453795.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


6. Heathcote KJ, Nair SB: The impact of modern techniques on the recurrence rate of inverted papilloma treated by endonasal surgery. Rhinology; 2009 Dec;47(4):339-44
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sinonasal inverted papilloma (IP) is a benign epithelial tumour which displays aggressive local behaviour, has a high local recurrence rate and the potential for malignant transformation.
  • [MeSH-major] Neoplasm Recurrence, Local / epidemiology. Nose Neoplasms / surgery. Otorhinolaryngologic Surgical Procedures / methods. Papilloma, Inverted / surgery
  • [MeSH-minor] Endoscopy. Humans. Nasal Cavity. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19936355.001).
  • [ISSN] 0300-0729
  • [Journal-full-title] Rhinology
  • [ISO-abbreviation] Rhinology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 54
  •  go-up   go-down


7. Diallo M, Cribier B, Scrivener Y: [Warty dyskeratoma: infundibular histogenesis. Anatomoclinical study of 43 cases]. Ann Dermatol Venereol; 2007 Aug-Sep;134(8-9):633-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The exact origin and classification of warty dyskeratoma in epithelial tumours are still debated.
  • The purpose of this study was to examine the relationship between this tumour and the pilosebaceous follicles.
  • DISCUSSION: Based on the histological and immunohistochemical findings, we proposed the hypothesis of benign epithelial tumour of follicular type, beginning in the pilar infundibulum.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma / pathology. Child. Darier Disease / pathology. Epithelium / pathology. Hair Follicle / pathology. Histiocytes / pathology. Humans. Keratin-1 / analysis. Keratin-10 / analysis. Keratin-17 / analysis. Keratin-19 / analysis. Keratin-5 / analysis. Keratoacanthoma / pathology. Lymphocytes / pathology. Middle Aged. Retrospective Studies. Sebaceous Glands / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925685.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Keratin-1; 0 / Keratin-19; 0 / Keratin-5; 147785-83-9 / Keratin-10
  •  go-up   go-down


8. Tuhkanen H, Soini Y, Kosma VM, Anttila M, Sironen R, Hämäläinen K, Kukkonen L, Virtanen I, Mannermaa A: Nuclear expression of Snail1 in borderline and malignant epithelial ovarian tumours is associated with tumour progression. BMC Cancer; 2009;9:289
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear expression of Snail1 in borderline and malignant epithelial ovarian tumours is associated with tumour progression.
  • BACKGROUND: Transcription factor Snail1 has a central role in induction of epithelial-mesenchymal transition (EMT).
  • The aim of the present study was to elucidate the expression of Snail1 protein during epithelial ovarian tumourigenesis and to study the association of Snail1 expression with clinicopathological factors and prognosis.
  • METHODS: Epithelial and stromal fibroblast-like fusiform cells of 14 normal ovarian samples, 21 benign, 24 borderline and 74 malignant epithelial ovarian tumours were studied for Snail1 protein using immunohistochemistry.
  • Nuclear expression of Snail1 protein in epithelial ovarian tumours was increased during tumour progression from precursor lesions into carcinomas both in epithelial (p = 0.006) and stromal cells (p = 0.007).
  • Nuclei of benign tumours (n = 21) were negative for Snail1.
  • In borderline tumours (n = 24) occasional positive epithelial cells were found in 2 (8%) samples and in 3 (13%) samples stromal cells were focally positive for Snail1.
  • In carcinomas (n = 74) focal Snail1 staining in epithelial cells was present in 17 (23%) tumours, and in stromal cells in 18 (24%) tumours.
  • Nuclear expression of Snail1 in epithelial or stromal cells was not associated with clinicopathological factors or prognosis.
  • CONCLUSION: Nuclear Snail1 expression seems to be related to tumour progression, and expression in borderline tumours indicates a role for Snail1 in early epithelial ovarian tumour development.
  • [MeSH-major] Epithelial Cells / metabolism. Gene Expression Regulation, Neoplastic. Nuclear Proteins / genetics. Ovarian Neoplasms / genetics. Transcription Factors / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):391-402 [12547698.001]
  • [Cites] Hum Pathol. 2003 Aug;34(8):756-63 [14506635.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Genes Dev. 2004 May 15;18(10):1131-43 [15155580.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S19-32 [15761464.001]
  • [Cites] Development. 2005 Jul;132(14):3151-61 [15983400.001]
  • [Cites] Angiogenesis. 2005;8(2):169-82 [16211363.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 [16493418.001]
  • [Cites] Virchows Arch. 2006 Mar;448(3):277-87 [16328348.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1345-53 [16642473.001]
  • [Cites] Oncogene. 2006 Aug 24;25(37):5134-44 [16568079.001]
  • [Cites] J Histochem Cytochem. 2006 Nov;54(11):1263-75 [16899764.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):520-8 [17024425.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):415-28 [17508028.001]
  • [Cites] Cells Tissues Organs. 2007;185(1-3):204-12 [17587826.001]
  • [Cites] Development. 2007 Nov;134(22):4073-81 [17965052.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10123-8 [17974953.001]
  • [Cites] Diagn Mol Pathol. 2007 Dec;16(4):222-8 [18043286.001]
  • [Cites] Br J Cancer. 2008 Jan 29;98(2):489-95 [18026186.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):995-1005 [18195328.001]
  • [Cites] J Mol Histol. 2008 Jun;39(3):283-94 [18327651.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4541-50 [18559498.001]
  • [Cites] Cancer Cell. 2008 Jul 8;14(1):79-89 [18598946.001]
  • [Cites] Histochem Cell Biol. 2008 Sep;130(3):481-94 [18648847.001]
  • [Cites] Virchows Arch. 2008 Sep;453(3):267-74 [18712413.001]
  • [Cites] J Cell Sci. 2008 Oct 15;121(Pt 20):3317-24 [18796538.001]
  • [Cites] J Cell Biol. 2009 Feb 9;184(3):399-408 [19188491.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):195-206 [19249678.001]
  • [Cites] Histochem Cell Biol. 2009 May;131(5):651-60 [19198871.001]
  • (PMID = 19695091.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / snail family transcription factors
  • [Other-IDs] NLM/ PMC3087336
  •  go-up   go-down


9. Ascani G, Messi M, Balercia P: [Surgical management of pleomorphic adenoma of the salivary glands: our experience]. G Chir; 2008 Aug-Sep;29(8-9):343-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pleomorphic adenoma is a benign epithelial tumour of adenoid structure preferentially arising from the parotid gland.
  • PATIENTS AND METHODS: This is an audit of a 15-year period where 347 pleomorphic adenomas of the salivary glands were treated by the authors.
  • The tumour occurred more often in females than in males (F:M=1.5).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18834565.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


10. Niang SO, Kane A, Diallo M, Choutah F, Dieng MT, Ndiaye B: Dermatosis papulosa nigra in Dakar, Senegal. Int J Dermatol; 2007 Oct;46 Suppl 1:45-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Dermatosis papulosa nigra (DPN) is a benign epithelial tumour, common in the black population.
  • Its benign character has meant that very few studies have been performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17919208.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Montironi R, Mazzucchelli R, Lopez-Beltran A, Martignoni G, Cheng L, Montorsi F, Scarpelli M: Cystic nephroma and mixed epithelial and stromal tumour of the kidney: opposite ends of the spectrum of the same entity? Eur Urol; 2008 Dec;54(6):1237-46
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for cystic nephroma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic nephroma and mixed epithelial and stromal tumour of the kidney: opposite ends of the spectrum of the same entity?
  • OBJECTIVES: The term "renal epithelial and stromal tumour" (REST) was proposed recently to encompass the spectrum of findings observed in cystic nephroma (CN) and mixed epithelial and stromal tumour (MEST) of the kidney.
  • Our aim was to review the broad spectrum of usual and unusual clinical and morphologic findings observed in CN and MEST.
  • RESULTS: CN and MEST have a remarkable similarity in sex predilection, age distribution, and morphologic attributes of both the epithelial and stromal components and immunohistochemical profile, albeit with variation in individual categories, with higher prevalence of stromal-to-epithelial ratio, prominent ovarian-like stroma, smaller cysts, and stromal luteinisation in MEST, and large cysts, thin septa, and low stromal-to-epithelial ratio in CN.
  • Rare and unusual morphologic features, such as endometrioid, cervical, and intestinal differentiation, and luteinised ovarian-like stroma, have been described in MEST.
  • The epithelial element occasionally shows estrogen and progesterone receptors.
  • Even though an aggressive behaviour has been reported in very few cases, in general both neoplasms are considered benign and surgical excision is curative.
  • [MeSH-major] Kidney Neoplasms / classification. Kidney Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2008 Dec;54(6):1245-6 [18006142.001]
  • [CommentIn] Eur Urol. 2009 Jul;56(1):e3 [19167806.001]
  • (PMID = 18006141.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 50
  •  go-up   go-down


12. Geoghegan S, Fitzpatrick JM, McGuire B, O'Malley KJ, Shaw C, Fabre A: A rare benign renal tumour presenting as polycythaemia in a teenage girl. Ir Med J; 2010 Apr;103(4):122-3
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare benign renal tumour presenting as polycythaemia in a teenage girl.
  • We present the case of a 15-year-old girl who presented with polycythemia.
  • Histology demonstrated a well circumscribed, focally encapsulated, round blue cell tumour showing areas of microcalcifications and numerous psammoma bodies.
  • This was consistent with a diagnosis of metanephric adenoma a rare benign epithelial renal tumour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20486320.001).
  • [ISSN] 0332-3102
  • [Journal-full-title] Irish medical journal
  • [ISO-abbreviation] Ir Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


13. Jordan S, Green A, Webb P: Benign epithelial ovarian tumours-cancer precursors or markers for ovarian cancer risk? Cancer Causes Control; 2006 Jun;17(5):623-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign epithelial ovarian tumours-cancer precursors or markers for ovarian cancer risk?
  • The natural history of the development of epithelial ovarian cancer remains obscure and no effective screening test exists.
  • In several human malignancies progression from benign to invasive tumour occurs, but this sequence has not been established for epithelial ovarian cancer.
  • We have reviewed epidemiological, histopathological and molecular studies of benign epithelial ovarian tumours to assess the evidence for and against such a progression in ovarian cancer.
  • These data suggest that a diagnosis of a benign ovarian cyst or tumour is associated with an increased risk of ovarian cancer later in life.
  • Current evidence also suggests that benign serous tumours can progress to low-grade serous cancer and that benign mucinous tumours can progress to mucinous cancer.
  • The more common high-grade serous ovarian cancers are likely to arise de novo.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / etiology. Ovarian Neoplasms / etiology. Precancerous Conditions / complications

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633908.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 63
  •  go-up   go-down


14. Bousdras VA, Bousdras KA, Newman L: Nasal obstruction as the first symptom in a patient with a calcifying epithelial odontogenic tumour (CEOT). Dent Update; 2009 Jul-Aug;36(6):350-2, 355

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal obstruction as the first symptom in a patient with a calcifying epithelial odontogenic tumour (CEOT).
  • Calcifying epithelial odontogenic tumour (CEOT), also known as Pindborg tumour, is a rare, benign odontogenic neoplasm.
  • Dental practitioners might be the first clinicians to come across such tumours, during investigation of missing or non-erupted maxillary teeth, ie canines, and they should be alerted by any unilateral nasal obstruction symptoms.
  • Diagnostic features and treatment options of the tumour are discussed in relation to its histological typing.
  • [MeSH-major] Maxillary Neoplasms / complications. Maxillary Sinus Neoplasms / complications. Nasal Obstruction / etiology. Odontogenic Tumors / complications. Odontogenic Tumors / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19743664.001).
  • [ISSN] 0305-5000
  • [Journal-full-title] Dental update
  • [ISO-abbreviation] Dent Update
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Rumelt S, Pe'er J, Rubin PA: The clinicopathological spectrum of benign peripunctal tumours. Graefes Arch Clin Exp Ophthalmol; 2005 Feb;243(2):113-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinicopathological spectrum of benign peripunctal tumours.
  • PURPOSE: Because of the rarity of peripunctal tumours and their clinical classification as conjunctival or eyelid tumours, they have gained little attention in the literature.
  • We conducted a retrospective study to illustrate the different clinical and histopathological spectrum of peripunctal tumours seen at two oculoplastics clinics.
  • METHODS: In a retrospective interventional clinicopathologic case series study, all the charts of patients with peripunctal tumours presented at an ophthalmic oncology clinic in Jerusalem, Israel and an oculoplastics clinic in Boston, USA were reviewed.
  • The tumours were classified as epithelial and non-epithelial tumours.
  • The symptoms caused by these tumours, their pattern of growth and their management were evaluated.
  • RESULTS: Fourteen peripunctal tumours were identified.
  • Seven histopathological types of peripunctal tumours of epithelial, subepithelial or melanocytic origin causing punctal occlusion or displacement were identified.
  • The tumours included compound and junctional naevi, non-pigmented compound naevus, epithelial, subepithelial inclusion cysts, verrucous and squamous papilloma, pyogenic granuloma and oncocytoma.
  • All the tumours were benign.
  • They involved the peripunctal or canalicular epithelium, the adjacent skin, the glandular epithelium or the subepithelium.
  • CONCLUSIONS: Peripunctal tumours are rare.
  • The location of peripunctal tumours potentially allows their extension from the conjunctival sac into the canaliculus and vice versa.
  • Therefore, it is best to ascertain free margins when the tumour is excised.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15558295.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Debnath SC, Adhyapok AK: Pleomorphic adenoma (benign mixed tumour) of the minor salivary glands of the upper lip. J Maxillofac Oral Surg; 2010 Jun;9(2):205-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic adenoma (benign mixed tumour) of the minor salivary glands of the upper lip.
  • Pleomorphic adenoma is the benign tumor of salivary glands, which originates from the myoepithelial cells and intercalated duct cells.
  • This tumor is more common in major salivary glands.
  • The tumor was a circumscribed, submucosal nodule, about 2.0 cm in diameter and was characterized by slow growth and rubbery consistency.
  • Complete excision was performed and the histopathological analysis showed an epithelial salivary gland tumor with islands of plasmacytoid cells, duct like structures, in a variable stroma with chondroid, fibrous and myxoid appearance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22190789.001).
  • [ISSN] 0974-942X
  • [Journal-full-title] Journal of maxillofacial and oral surgery
  • [ISO-abbreviation] J Maxillofac Oral Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3244097
  • [Keywords] NOTNLM ; Minor salivary glands / Pleomorphic adenoma / Upper lip
  •  go-up   go-down


17. Zhong Y, Wang L, Li T, Chen XM: Calcifying epithelial odontogenic tumour showing malignant transformation: a case report and review of the literature. Chin J Dent Res; 2010;13(2):157-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcifying epithelial odontogenic tumour showing malignant transformation: a case report and review of the literature.
  • Calcifying epithelial odontogenic tumour (CEOT) is a rare and benign odontogenic neoplasm that affects the jaws.
  • [MeSH-minor] Humans. Keratin-19 / analysis. Ki-67 Antigen / analysis. Male. Middle Aged. Odontogenic Tumors / pathology. Odontogenic Tumors / surgery. Skin Neoplasms / pathology. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21264368.001).
  • [ISSN] 1462-6446
  • [Journal-full-title] The Chinese journal of dental research : the official journal of the Scientific Section of the Chinese Stomatological Association (CSA)
  • [ISO-abbreviation] Chin J Dent Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-19; 0 / Ki-67 Antigen; Calcifying Epithelial Odontogenic Tumor
  •  go-up   go-down


18. Chang KC, Wu MH, Jones D, Chen FF, Tseng YL: Activation of STAT3 in thymic epithelial tumours correlates with tumour type and clinical behaviour. J Pathol; 2006 Oct;210(2):224-33
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of STAT3 in thymic epithelial tumours correlates with tumour type and clinical behaviour.
  • The association of STAT3 activation with thymic epithelial tumours (TETs) and myasthenia gravis (MG) has not been elucidated.
  • It was found that STAT3 activation in thymic epithelial cells (TECs), as evidenced by pSTAT3 expression and/or nuclear STAT3, was present in the majority of non-neoplastic thymuses (88%, 22/25), including those from young children, but not in fetal thymus.
  • These data provide the first evidence that constitutive STAT3 activation is seen in both benign and neoplastic thymic tissue and is associated with the persistence of thymic tissue and the presence of MG.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Neoplasm Proteins / metabolism. STAT3 Transcription Factor / metabolism. Thymus Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aging / metabolism. Child. Child, Preschool. Female. Humans. Immunoenzyme Techniques. Infant. Infant, Newborn. Male. Middle Aged. Myasthenia Gravis / etiology. Myasthenia Gravis / metabolism. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Survival Analysis. Thymoma / complications. Thymoma / metabolism. Thymoma / pathology. Thymus Gland / growth & development. Thymus Gland / metabolism. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917804.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / STAT3 Transcription Factor
  •  go-up   go-down


19. Ungari C, Paparo F, Colangeli W, Iannetti G: Parotid glands tumours: overview of a 10-year experience with 282 patients, focusing on 231 benign epithelial neoplasms. Eur Rev Med Pharmacol Sci; 2008 Sep-Oct;12(5):321-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid glands tumours: overview of a 10-year experience with 282 patients, focusing on 231 benign epithelial neoplasms.
  • Salivary gland tumours are uncommon, representing less than 6% of head and neck neoplasm.
  • Pleomorphic adenoma is the most common benign epithelial salivary gland neoplasm, comprising 50%-74% of all parotid tumours.
  • It is followed by Warthin's tumour (4-14%).
  • The authors retrospectively reviewed 282 eligible patients surgically treated for parotid gland tumours in the last 10 years, focusing on 231 benign epithelial neoplasms.
  • The diagnosis of a parotid gland neoplasm must be considered in any patient presenting with a lump near the mandible.
  • Smoking habit is important in Warthin's tumour pathogenesis.
  • Tumour pseudopodia and capsule ruptures are recognised factors involved in pleomorphic adenoma recurrences but also tumour multicentricity might play an important role.
  • [MeSH-major] Epithelium / surgery. Parotid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19024217.001).
  • [ISSN] 1128-3602
  • [Journal-full-title] European review for medical and pharmacological sciences
  • [ISO-abbreviation] Eur Rev Med Pharmacol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


20. Pawlicki J, Król R, Kajor M, Ziaja J: [Case of malignant tumour phyllodes converting to fibrosarcoma]. Pol Merkur Lekarski; 2007 Mar;22(129):215-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of malignant tumour phyllodes converting to fibrosarcoma].
  • Tumour phyllodes is rare breast neoplasm.
  • Tumours phyllodes are composed of hypercellular mesenchymal stroma and epithelial elements.
  • They are commonly classified as benign, rarely as borderline or malignant.
  • There is a case of large (28 x 24 cm) malignant tumour phyllodes presented in the article.
  • After surgical treatment of recurrent tumours (fibrosarcoma form) occurred two times during 1 year time.
  • In spite of unfavorable prognostic features of the tumour (large size, malignant histological character) and recurrences, final therapeutic effect was good.
  • [MeSH-major] Breast Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Fibrosarcoma / pathology. Neoplasm Recurrence, Local / pathology. Phyllodes Tumor / pathology

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17682679.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


21. Cordero Coma M, Yilmaz T, Foster CS: Tumour necrosis factor-alpha in conjunctivae affected by ocular cicatricial pemphigoid. Acta Ophthalmol Scand; 2007 Nov;85(7):753-5
MedlinePlus Health Information. consumer health - Pemphigus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour necrosis factor-alpha in conjunctivae affected by ocular cicatricial pemphigoid.
  • PURPOSE: The presence of tumour necrosis factor-alpha (TNF-alpha) in conjunctivae affected by ocular cicatricial pemphigoid (OCP) was investigated.
  • The expression of TNF-alpha was detected in both epithelial and stromal cells of conjunctivae from OCP patients.
  • [MeSH-major] Conjunctiva / metabolism. Conjunctivitis, Allergic / metabolism. Pemphigoid, Benign Mucous Membrane / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • Genetic Alliance. consumer health - Cicatricial Pemphigoid.
  • Genetic Alliance. consumer health - Ocular cicatricial pemphigoid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488321.001).
  • [ISSN] 1395-3907
  • [Journal-full-title] Acta ophthalmologica Scandinavica
  • [ISO-abbreviation] Acta Ophthalmol Scand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


22. Păun I, Mogoş D, Păun M, Teodorescu M, Florescu M, Tenovici M, Mogoş G: [Diseases mimicking advanced-stage epithelial ovarian cancer]. Chirurgia (Bucur); 2010 Jul-Aug;105(4):541-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diseases mimicking advanced-stage epithelial ovarian cancer].
  • [Transliterated title] Afecţiuni mimând cancerul ovarian epitelial în stadiu avansat.
  • This paper draws attention towards 3 cases with different pathologies all of which suggesting however both clinically and by imaging means as the most likely diagnosis advanced-stage epithelial ovarian cancer since all these three postmenopausal women had been admitted to the hospital with ascites, pelvic masses and deterioration of the physical wellbeing (fatigue, decreased appetite, weight loss, pallor).
  • Findings during exploratory laparotomy on all these three pacients included ascites (hemorragic in one case) diffuse tumorous implants throughout the abdominal and pelvic peritoneal surfaces (in two cases) and the ovarian tumour.
  • Postoperatively, the final histopathologic diagnoses consisted of primary peritoneal carcinoma (one pacient), peritoneal tuberculosis (TB, one pacient) and hepatic cirrosis with an incidental benign adnexial mass (one pacient).
  • Moreover, nonmalignant ovarian tumours were certified in all three cases under current presentation.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Antitubercular Agents / therapeutic use. Ascites / diagnosis. Diagnosis, Differential. Diagnostic Errors. Drug Therapy, Combination. Female. Humans. Middle Aged. Neoplasm Staging. Ovariectomy. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20941979.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antitubercular Agents
  •  go-up   go-down


23. Münz M, Zeidler R, Gires O: The tumour-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP. Cancer Lett; 2005 Jul 8;225(1):151-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tumour-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP.
  • The epithelial cell adhesion molecule, EpCAM, is a transmembrane glycoprotein associated with both benign and malignant proliferation.
  • In cancer cells, expression levels of this tumour-associated antigen correlate positively with the grade of dysplasia and are also a negative prognostic factor for breast cancer patients.
  • De novo expression of EpCAM resulted in the rapid upregulation of the proto-oncogene c-Myc along with enhanced cell proliferation and metabolism.
  • Here, we analyzed the effects of EpCAM onto the proteome of epithelial cells.
  • Taken together, these results provide further evidence for the direct involvement of EpCAM in signalling processes, gene regulation, and cellular metabolism supporting its important role in tumour biology.
  • [MeSH-major] Antigens, Neoplasm / physiology. Carcinoma, Squamous Cell / genetics. Cell Adhesion Molecules / physiology. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Antigens, Differentiation. Carrier Proteins. Cell Proliferation. Epithelial Cells. Fatty Acid-Binding Proteins. Fatty Acids. Genes, myc. Humans. Proteome. Signal Transduction. Tumor Cells, Cultured. Up-Regulation

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15922867.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Antigens, Neoplasm; 0 / Carrier Proteins; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / FABP5 protein, human; 0 / Fatty Acid-Binding Proteins; 0 / Fatty Acids; 0 / Proteome
  •  go-up   go-down


24. González Bosquet E, Sunol M, Callejo J, Lailla JM: Uterine adenosarcoma diagnosed following hysteroscopic resection of an intrauterine tumour. Eur J Gynaecol Oncol; 2005;26(4):415-7
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine adenosarcoma diagnosed following hysteroscopic resection of an intrauterine tumour.
  • Uterine adenosarcoma is a mixed müllerian tumour consisting of a benign epithelial component and a malignant stromal component.
  • It is a rare tumour that represents 8% of uterine sarcomas.
  • We present a case of a 61-year-old woman who underwent a surgical hysteroscopy for postmenopausal metrorrhagia and thickened endometrium detected by ultrasonography.
  • The pathologic diagnosis of the tumour removed by hysteroscopy was uterine adenosarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16122191.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


25. Beaufour A, Cazals-Hatem D, Regimbeau JM, Ponsot P, Degott C, Belghiti J, Sauvanet A: [Osteoclastic giant cell tumour of the pancreas]. Gastroenterol Clin Biol; 2005 Feb;29(2):197-200
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Osteoclastic giant cell tumour of the pancreas].
  • Osteoclast giant cell tumours are bone tumours that occur in adults, and that are considered benign by WHO but locally aggressive.
  • Strictly identical tumours are described in the pancreas, without simultaneous bone localization.
  • We report the case of a 62-year woman with an osteoclast giant cell tumour of the distal pancreas, without any epithelial component, which was diagnosed after pancreatic resection and with no signs of recurrence after a 24-month follow-up.
  • These pancreatic tumours are rare, with a very poor prognosis, an unclear histogenesis; they are often confused with pleomorphic or undifferentiated pancreatic carcinomas including a component of osteoclast giant cell.
  • These osteoclast giant cell tumours of the pancreas usually present as large cystic tumours.
  • [MeSH-major] Giant Cell Tumor of Bone. Pancreatic Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15795672.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


26. El-Gehani R, Orafi M, Elarbi M, Subhashraj K: Benign tumours of orofacial region at Benghazi, Libya: a study of 405 cases. J Craniomaxillofac Surg; 2009 Oct;37(7):370-5
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign tumours of orofacial region at Benghazi, Libya: a study of 405 cases.
  • INTRODUCTION: Although benign tumours are thought to be relatively uncommon in the orofacial region, the incidence differs according to the country.
  • The purpose of this study was to systematically analyse the incidence of benign tumours of maxillofacial region within the Libyan population.
  • MATERIAL AND METHODS: A total of 405 cases of benign tumours reported at the Faculty of Dentistry, Arab Medical Science University, Libyan Arab Jamahiriya between 1991 and 2007 were analysed.
  • RESULTS: Keratocystic odontogenic tumour (35.1%) was the most common.
  • Among the non-odontogenic tumours, there were 85 cases of fibrous and adipose tissue origin (33%), 66 cases of bone tumours (26%), 51 cases of epithelial tumours (20%), 37 cases of vascular origin (14%) and 18 neurogenic (7%).
  • CONCLUSION: In comparison with other international studies, the incidence of benign tumours of orofacial region is relatively lower in Libyan population.
  • [MeSH-major] Facial Neoplasms / epidemiology. Jaw Diseases / epidemiology. Mouth Neoplasms / epidemiology. Odontogenic Cysts / epidemiology. Odontogenic Tumors / epidemiology

  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19362008.001).
  • [ISSN] 1878-4119
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


27. Moreira PR, Guimarães MM, Gomes CC, Diniz MG, Brito JA, de Castro WH, Gomez RS: Methylation frequencies of cell-cycle associated genes in epithelial odontogenic tumours. Arch Oral Biol; 2009 Oct;54(10):893-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation frequencies of cell-cycle associated genes in epithelial odontogenic tumours.
  • OBJECTIVE: The benign epithelial odontogenic tumours constitute a group of lesions derived from epithelial elements of the tooth-forming apparatus.
  • This group includes lesions of different biological behaviour, such as ameloblastoma, calcifying cystic odontogenic tumour (CCOT) and adenomatoid odontogenic tumour (AOT).
  • The aim of this study was to investigate the methylation status of P16, P21, P27, P53 and RB1 genes in epithelial odontogenic tumours.
  • A high percentage of the odontogenic tumours analysed showed methylation of the P21 gene, in contrast to dental follicles.
  • CONCLUSIONS: Epithelial odontogenic tumours show a distinct methylation profile in cell-cycle associated genes.
  • In addition to this, the current findings show that epigenetic alterations are common events in epithelial odontogenic tumours.
  • [MeSH-major] Cell Cycle Proteins / genetics. DNA Methylation / genetics. DNA, Neoplasm / metabolism. Neoplasm Proteins / genetics. Odontogenic Tumors / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Ameloblastoma / genetics. Ameloblastoma / metabolism. Dental Sac / metabolism. Epithelial Cells / metabolism. Humans. Odontogenic Cyst, Calcifying / genetics. Odontogenic Cyst, Calcifying / metabolism. Polymerase Chain Reaction / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19679296.001).
  • [ISSN] 1879-1506
  • [Journal-full-title] Archives of oral biology
  • [ISO-abbreviation] Arch. Oral Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins
  •  go-up   go-down


28. Angiero F: Ectomesenchymal chondromyxoid tumour of the tongue. A review of histological and immunohistochemical features. Anticancer Res; 2010 Nov;30(11):4685-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectomesenchymal chondromyxoid tumour of the tongue. A review of histological and immunohistochemical features.
  • BACKGROUND: Ectomesenchymal chondromyxoid tumour (ECT) is a rare, benign neoplasm of uncertain histogenesis, which appears to exclusively involve the oral cavity, particularly the tongue.
  • CASE REPORT: We report the case of a 27-year-old woman with a 0.7 cm tumoral lesion of 3 months' duration on the dorsum of the tongue.
  • Immunohistochemistry revealed positivity of the neoplastic cells for antibodies directed against S-100, glial fibrillary acidic protein and vimentin, plus negativity for CD-57(leu-7), epithelial membrane antigen, smooth muscle actin, desmin and cytokeratin AE1-AE3.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21115924.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Desmin; 0 / Glial Fibrillary Acidic Protein; 0 / S100 Proteins; 0 / Vimentin
  •  go-up   go-down


29. Andikyan V, Taylor HS: WT1 represses HOX gene expression in the regulation of gynaecologic tumour histologic type. J Cell Mol Med; 2009 Nov-Dec;13(11-12):4522-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1 represses HOX gene expression in the regulation of gynaecologic tumour histologic type.
  • The homeobox gene HOXA10 controls uterine organogenesis during embryonic development and similarly is expressed in endometroid epithelial ovarian cancer.
  • Here we confirmed aberrant regulation of HOXA10 expression in epithelial uterine and ovarian carcinomas.
  • We identified a HOXA10 epithelial regulatory element containing an enhancer that drove HOXA10 expression specifically in gynaecologic epithelium.
  • We further identified an adjoining dominant repressor element that restricted regulation by the epithelial enhancer to a subset of epithelial cell types.
  • We identified a strong inverse correlation between HOXA10 expression and that of the Wilms' Tumour 1 (WT1) gene in multiple benign and malignant gynaecologic tissues, suggesting functionality of the WT1 sites in the repressor.
  • Mutation of the two WT1 binding sites abolished WT1 binding to the element as well as the ability to affect epithelial enhancer activity in reporter assays.
  • This suggests that Gynaecologic epithelial histologic type is regulated by WT1 expression through its selective repression of HOX genes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):449-55 [15297187.001]
  • [Cites] Endocrinology. 2004 May;145(5):2291-6 [14726435.001]
  • [Cites] Nature. 1978 Dec 7;276(5688):565-70 [103000.001]
  • [Cites] Nature. 1990 Jul 12;346(6280):194-7 [2164159.001]
  • [Cites] Cell. 1992 Jan 24;68(2):283-302 [1346368.001]
  • [Cites] Blood. 1992 Nov 15;80(10):2445-53 [1358259.001]
  • [Cites] Oncogene. 1992 Nov;7(11):2141-9 [1331933.001]
  • [Cites] Mech Dev. 1993 Jan;40(1-2):85-97 [8382938.001]
  • [Cites] Cell. 1994 Jul 29;78(2):191-201 [7913880.001]
  • [Cites] Nature. 1995 Mar 30;374(6521):460-3 [7700356.001]
  • [Cites] Development. 1995 May;121(5):1373-85 [7789268.001]
  • [Cites] Nat Genet. 1996 Jul;13(3):284-9 [8673126.001]
  • [Cites] Dev Dyn. 1997 Apr;208(4):454-65 [9097018.001]
  • [Cites] Biol Reprod. 1997 Dec;57(6):1338-45 [9408238.001]
  • [Cites] Hum Mol Genet. 1998 Apr;7(4):709-14 [9499425.001]
  • [Cites] J Clin Invest. 1998 Apr 1;101(7):1379-84 [9525980.001]
  • [Cites] Curr Opin Genet Dev. 1998 Aug;8(4):423-9 [9729718.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):437-42 [10053122.001]
  • [Cites] Hum Reprod. 1999 May;14(5):1328-31 [10325287.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):522-8 [15494461.001]
  • [Cites] Nat Med. 2005 May;11(5):531-7 [15821746.001]
  • [Cites] Pediatrics. 2005 Oct;116(4):984-8 [16199712.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2428-37 [16199152.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):889-97 [16424022.001]
  • [Cites] Int J Gynecol Pathol. 2000 Apr;19(2):158-63 [10782413.001]
  • [Cites] Biochem Pharmacol. 1999 Dec 15;58(12):1851-7 [10591139.001]
  • [Cites] Reprod Sci. 2007 Sep;14(6):605-14 [17959889.001]
  • [Cites] Semin Reprod Med. 2000;18(1):81-9 [11299523.001]
  • [Cites] Pediatr Nephrol. 2001 Apr;16(4):335-9 [11354777.001]
  • [Cites] Gene. 2001 Aug 8;273(2):141-61 [11595161.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Sep 10;110(1):111-3 [12932885.001]
  • [Cites] Cancer Biol Ther. 2004 Jun;3(6):568-72 [15044858.001]
  • (PMID = 19017365.001).
  • [ISSN] 1582-4934
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD036887; United States / NICHD NIH HHS / HD / R29 HD036887; United States / NICHD NIH HHS / HD / U54 HD052668-05; United States / NICHD NIH HHS / HD / U54 HD052668; United States / NICHD NIH HHS / HD / HD062668; United States / NICHD NIH HHS / HD / R01 HD036887
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Repressor Proteins; 0 / WT1 Proteins; 140441-81-2 / HOXA10 protein, human
  • [Other-IDs] NLM/ NIHMS293627; NLM/ PMC3107857
  •  go-up   go-down


30. Zaman S, Majid S, Hussain M, Chughtai O, Mahboob J, Chughtai S: A retrospective study of ovarian tumours and tumour-like lesions. J Ayub Med Coll Abbottabad; 2010 Jan-Mar;22(1):104-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective study of ovarian tumours and tumour-like lesions.
  • METHODS: The study was a retrospective review of all cases of ovarian cancer, benign ovarian neoplasm and functional ovarian cysts received during Jan-Dec 2008 at Chughtai's Lahore Laboratory.
  • Non-neoplastic cysts were more common (343, 68.87%) than neoplastic tumours (155, 31.12%).
  • Among the neoplastic tumours 78.70% were benign and 21.29% were malignant.
  • Benign serous cysts were the commonest benign tumour followed by mature cystic teratoma and mucinous cyst.
  • Serous cystadenocarcinoma was the commonest malignant tumour followed closely by endometrioid carcinoma and granulosa cell tumour.
  • Krukenberg tumour, tumour metastatic to ovaries and non-Hodgkins lymphoma was also diagnosed during this period.
  • Malignant germ cell tumours were seen in much younger age group followed by sex cord stromal tumours.
  • Epithelial tumours were seen in much older age group.
  • CONCLUSION: The morphologic diversity of ovarian masses poses many challenges.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21409917.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


31. Matull WR, Andreola F, Loh A, Adiguzel Z, Deheragoda M, Qureshi U, Batra SK, Swallow DM, Pereira SP: MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer. Br J Cancer; 2008 May 20;98(10):1675-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer.
  • Alterations in epithelial mucin expression are associated with carcinogenesis, but there are few data in biliary tract cancer (BTC).
  • In pancreatic malignancy, MUC4 is a diagnostic and prognostic tumour marker, whereas MUC5AC has been proposed as a sensitive serological marker for BTC.
  • In bile, MUC4 protein was detected in 27% of BTC and 29% of primary sclerosing cholangitis (PSC) cases, but not in other benign and malignant biliary diseases (P<0.01 and P=0.06).
  • qPCR revealed a 1.9-fold increased MUC4 mRNA expression in BTC patients' bile compared with benign disease.
  • In archived tissues, MUC4 protein was detected in 37% of BTC but in none of the benign samples (P=0.03).
  • Biliary MUC4 and serum MUC5AC are highly specific tumour-associated mucins that may be useful in the diagnosis and formulation of therapeutic strategies in BTC.
  • [MeSH-major] Bile / metabolism. Biliary Tract Neoplasms / metabolism. Biomarkers, Tumor / metabolism. Mucins / blood. Mucins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Mucin 5AC. Mucin-4. Neoplasm Staging. Predictive Value of Tests. Prospective Studies. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2007 Aug 6;97(3):345-57 [17595659.001]
  • [Cites] World J Gastroenterol. 2007 Mar 14;13(10):1505-15 [17461441.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9 [11573044.001]
  • [Cites] Dig Dis Sci. 2001 Oct;46(10):2166-72 [11680592.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):719-26 [11821453.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Apr;43(4):1004-11 [11923240.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):336-43 [11992401.001]
  • [Cites] Am J Clin Pathol. 2002 May;117(5):791-6 [12090430.001]
  • [Cites] Gut. 2002 Nov;51 Suppl 6:VI1-9 [12376491.001]
  • [Cites] Bioessays. 2003 Jan;25(1):66-71 [12508284.001]
  • [Cites] Cancer Lett. 2003 May 30;195(1):93-9 [12767517.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1438-43 [14508831.001]
  • [Cites] Hybrid Hybridomics. 2003 Oct;22(5):293-9 [14678646.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] J Histochem Cytochem. 2004 Feb;52(2):253-61 [14729877.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):622-30 [14744777.001]
  • [Cites] Hepatology. 2004 Jan;39(1):220-9 [14752841.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):139-54 [15192787.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1633-8 [15494719.001]
  • [Cites] Essays Biochem. 1985;20:40-76 [3896779.001]
  • [Cites] Biochem J. 1996 Aug 15;318 ( Pt 1):319-24 [8761488.001]
  • [Cites] J Cell Physiol. 2005 Jul;204(1):166-77 [15672420.001]
  • [Cites] J Clin Pathol. 2005 Aug;58(8):845-52 [16049287.001]
  • [Cites] Aliment Pharmacol Ther. 2006 May 1;23(9):1287-96 [16629933.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):19310-9 [16690615.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4257-64 [16857800.001]
  • [Cites] J Biol Chem. 2006 Sep 29;281(39):29411-20 [16891313.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):433-6 [17234748.001]
  • [Cites] Cancer Lett. 2007 Mar 18;247(2):301-8 [16793202.001]
  • [Cites] Eur J Biochem. 2000 Jul;267(14):4536-44 [10880978.001]
  • (PMID = 18475301.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ G0801588; United Kingdom / Cancer Research UK / / C24036/A7839
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC4 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-4; 0 / Mucins
  • [Other-IDs] NLM/ PMC2391120
  •  go-up   go-down


32. Awasthi R, O'Neill JK, Keen CE, Sarsfield PT, Devaraj VS, Stone CA, Smith ME: Biphasic solitary fibrous tumour: a report of two cases with epithelioid features. Virchows Arch; 2006 Mar;448(3):306-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biphasic solitary fibrous tumour: a report of two cases with epithelioid features.
  • We present two cases of solitary fibrous tumour (SFT) showing biphasic morphology with a spectrum of malignant epithelioid components.
  • Both cases showed biphasic morphology with some areas having typical benign spindled SFT morphology (including CD34 expression) and other areas having a malignant epithelioid appearance.
  • In one of the cases, the epithelioid area, which was well circumscribed and showed packeting of cell groups, demonstrated expression of cytokeratin and epithelial cadherin but not of CD34.
  • In the second case, the immunophenotype of the epithelioid component was similar to that of the benign SFT component.
  • These findings suggest that epithelioid change in SFT shows a range of differentiation at one end, similar to that of a standard SFT, and at the other end, possibly acquiring epithelial characteristics.
  • [MeSH-major] Epithelioid Cells / pathology. Soft Tissue Neoplasms / pathology. Solitary Fibrous Tumors / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Sarcoma, Synovial / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16244869.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


33. Hahne JC, Kummer S, Heukamp LC, Fuchs T, Gun M, Langer B, Von Ruecker A, Wernert N: Regulation of protein tyrosine kinases in tumour cells by the transcription factor Ets-1. Int J Oncol; 2009 Nov;35(5):989-96

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of protein tyrosine kinases in tumour cells by the transcription factor Ets-1.
  • Aberration in PTK signalling occurs in inflammatory diseases and diabetes, and aberrant expression can lead to benign proliferative conditions as well as to various forms of cancer.
  • Therefore, these enzymes are now used as targets in the treatment of different tumours.
  • Ets-1 is a transcription factor expressed in a number of human malignancies with demonstrated roles within both neoplastic cells and tumour stroma.
  • These roles include stimulation of tumour cell proliferation and invasion as well as tumour angiogenesis.
  • We investigated the role of Ets-1 in transcriptional regulation of a panel of 89 PTKs in epithelial HeLa tumour cells.
  • The data presented here underscore the importance of Ets-1 in tumour development and progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787252.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ETS1 protein, human; 0 / Proto-Oncogene Protein c-ets-1; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


34. Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P, Ruiz i Altaba A: Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med; 2009 Sep;1(6-7):338-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion.
  • Human colon cancers often start as benign adenomas through loss of APC, leading to enhanced beta CATENIN (beta CAT)/TCF function.
  • We find that epithelial cells of human colon carcinomas (CCs) and their stem cells of all stages harbour an active HH-GLI pathway.
  • We show that the growth of CC xenografts, their recurrence and metastases require HH-GLI function, which induces a robust epithelial-to-mesenchymal transition (EMT).
  • Moreover, using a novel tumour cell competition assay we show that the self-renewal of CC stem cells in vivo relies on HH-GLI activity.
  • Targeting HH-GLI1, directly or indirectly, is thus predicted to decrease tumour bulk and eradicate CC stem cells and metastases.
  • [MeSH-major] Carcinoma / metabolism. Colonic Neoplasms / metabolism. Epithelial Cells / metabolism. Hedgehog Proteins / metabolism. Neoplastic Stem Cells / cytology. Transcription Factors / metabolism
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cells, Cultured. Gene Expression Regulation, Neoplastic. Humans. Mice. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Signal Transduction / drug effects. Veratrum Alkaloids / therapeutic use

  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2006 Feb 20;233(1):117-23 [16473672.001]
  • [Cites] Virchows Arch. 2009 Apr;454(4):369-79 [19280222.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] Development. 2001 Dec;128(24):5201-12 [11748155.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Development. 2004 Jan;131(2):337-45 [14681189.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):277-82 [14770182.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]
  • [Cites] J Pathol. 2004 Aug;203(4):909-17 [15258993.001]
  • [Cites] Dev Biol. 2004 Sep 15;273(2):257-75 [15328011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Teratology. 1970 May;3(2):175-80 [4986632.001]
  • [Cites] Lipids. 1978 Oct;13(10):708-15 [723484.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] Nature. 1997 Oct 23;389(6653):876-81 [9349822.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Development. 1998 Sep;125(18):3553-62 [9716521.001]
  • [Cites] Development. 1999 Jun;126(14):3205-16 [10375510.001]
  • [Cites] Development. 2005 Jan;132(2):279-89 [15590741.001]
  • [Cites] Mech Dev. 2005 Feb;122(2):223-30 [15652709.001]
  • [Cites] Oncogene. 2006 Jan 26;25(4):609-21 [16158046.001]
  • [Cites] Gastroenterology. 2009 Jun;136(7):2187-2194.e1 [19324043.001]
  • [Cites] Surgery. 2006 May;139(5):665-70 [16701100.001]
  • [Cites] Gut. 2006 Jul;55(7):991-9 [16299030.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] J Gastroenterol. 2006 Dec;41(12):1238-9 [17287906.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900 [17392427.001]
  • [Cites] World J Gastroenterol. 2007 Mar 21;13(11):1659-65 [17461467.001]
  • [Cites] Trends Cell Biol. 2007 Sep;17(9):438-47 [17845852.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2622-7 [17683069.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):638-48 [17932721.001]
  • [Cites] Cell Stem Cell. 2007 Oct 11;1(4):389-402 [18371377.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13427-32 [18765800.001]
  • [Cites] Nature. 2008 Sep 18;455(7211):406-10 [18754008.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):281-3 [18835029.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):603-7 [19092805.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4254-9 [19246386.001]
  • [Cites] EMBO J. 2009 Mar 18;28(6):663-76 [19214186.001]
  • [CommentIn] EMBO Mol Med. 2010 Oct;2(10):385-6; author reply 386-7 [20721989.001]
  • [CommentIn] EMBO Mol Med. 2009 Sep;1(6-7):300-2 [20049733.001]
  • (PMID = 20049737.001).
  • [ISSN] 1757-4684
  • [Journal-full-title] EMBO molecular medicine
  • [ISO-abbreviation] EMBO Mol Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Transcription Factors; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ PMC3378144
  •  go-up   go-down


35. Kothandaraman N, Bajic VB, Brendan PN, Huak CY, Keow PB, Razvi K, Salto-Tellez M, Choolani M: E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer. BMC Cancer; 2010;10:64
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer.
  • BACKGROUND: Ovarian epithelial cancer (OEC) usually presents in the later stages of the disease.
  • Factors, especially those associated with cell-cycle genes, affecting the genesis and tumour progression for ovarian cancer are largely unknown.
  • Our hypothesis was supported by our tissue array experiments that showed E2F5 expression only in OEC samples but not in normal and benign tissues, and by significantly positively biased expression in serum samples done using western blotting studies.
  • RESULTS: Analysis of clinical cases shows that of the E2F5 status is characteristic for a different population group than one covered by CA125, a conventional OEC biomarker.
  • E2F5 used in different combinations with CA125 for distinguishing malignant cyst from benign cyst shows that the presence of CA125 or E2F5 increases sensitivity of OEC detection to 97.9% (an increase from 87.5% if only CA125 is used) and, more importantly, the presence of both CA125 and E2F5 increases specificity of OEC to 72.5% (an increase from 55% if only CA125 is used).
  • Furthermore, detection of malignancy status in 86 cases (38 benign, 48 early and late OEC) shows that the use of E2F5 status in combination with other clinical characteristics allows for an improved detection of malignant cases with sensitivity, specificity, F-measure and accuracy of 97.92%, 97.37%, 97.92% and 97.67%, respectively.
  • [MeSH-minor] Adult. Aged. Algorithms. Biomarkers, Tumor / metabolism. CA-125 Antigen / biosynthesis. Disease Progression. Female. Humans. Middle Aged. Neoplasm Metastasis. Reproducibility of Results. Sensitivity and Specificity


36. Panchal L, Vaideeswar P, Kathpal D, Madiwale CV, Prabhat DP: Sino-nasal epithelial tumours: a pathological study of 69 cases. J Postgrad Med; 2005 Jan-Mar;51(1):30-4; discussion 34-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sino-nasal epithelial tumours: a pathological study of 69 cases.
  • BACKGROUND: Epithelial neoplasms are uncommon lesions affecting the sino-nasal tract.
  • AIM: To study the incidence, mode of presentation and histological types of sino-nasal epithelial tumours in the surgical pathology material.
  • SETTING AND DESIGN: Retrospective retrieval of all sino-nasal tumours and analysis of epithelial tumours.
  • MATERIALS AND METHODS: All sino-nasal epithelial tumours, biopsied or surgically excised over a period of ten years, were studied.
  • The tumours were classified as benign or malignant.
  • RESULTS: In ten years, there were 120 sino-nasal tumours representing 0.14% of all the surgical specimens received.
  • Sixty-nine epithelial tumours (59.2%) outnumbered the non-epithelial tumours and were diagnosed on the basis of histopathology.
  • Twenty were benign and 49 malignant; occurring predominantly in males.
  • Benign lesions included four squamous papillomas and 16 inverted papillomas, with recurrence in three inverted papillomas (21%).
  • Squamous cell carcinomas were the commonest among malignant tumours and four of these were associated with inverted or cylindrical cell papilloma.
  • The second most frequent malignant tumour was adenoid cystic carcinoma with eight cases.
  • CONCLUSION: Sino-nasal epithelial tumours are rare lesions, with male preponderance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793335.001).
  • [ISSN] 0022-3859
  • [Journal-full-title] Journal of postgraduate medicine
  • [ISO-abbreviation] J Postgrad Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


37. Busund LT, Richardsen E, Busund R, Ukkonen T, Bjørnsen T, Busch C, Stalsberg H: Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol; 2005 Apr;58(4):361-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant expression of IGFBP2 in breast cancer compared with benign lesions.
  • Because IGFs have mitogenic effects on mammary epithelia, this study investigated IGFBP2 expression in mammary tissues of different benign and malignant entities.
  • METHODS: Immunohistochemistry was used to study correlations between the presence and intensity of IGFBP2 staining and tumour type and grade, in addition to steroid hormone receptor status, in 120 breast specimens.
  • [MeSH-major] Breast Neoplasms / chemistry. Insulin-Like Growth Factor Binding Protein 2 / analysis. Neoplasm Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma in Situ / chemistry. Carcinoma in Situ / pathology. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Hyperplasia / metabolism. Image Processing, Computer-Assisted / methods. Immunohistochemistry / methods. Mammary Glands, Human / chemistry. Mammary Glands, Human / pathology. Middle Aged. Neoplasm Invasiveness / pathology. Precancerous Conditions / chemistry. Precancerous Conditions / pathology. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2003 Apr;442(4):329-35 [12684767.001]
  • [Cites] Growth Regul. 1993 Mar;3(1):5-8 [7683529.001]
  • [Cites] Horm Res. 1986;24(2-3):160-5 [3530939.001]
  • [Cites] Biochem Biophys Res Commun. 1988 Oct 14;156(1):199-204 [2972283.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Jan 16;158(1):38-44 [2463838.001]
  • [Cites] Mol Endocrinol. 1989 Mar;3(3):509-17 [2747657.001]
  • [Cites] Endocrinology. 1990 Jul;127(1):1-4 [2163304.001]
  • [Cites] Endocrinology. 1990 Dec;127(6):2679-86 [1701124.001]
  • [Cites] Cell Growth Differ. 1990 Jul;1(7):325-31 [2177632.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] J Cell Biochem. 1992 Feb;48(2):215-26 [1377702.001]
  • [Cites] Growth Regul. 1993 Mar;3(1):82-4 [7683542.001]
  • [Cites] Dis Markers. 1993 Sep;11(2-3):53-70 [8261734.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2934-42 [7514495.001]
  • [Cites] J Natl Cancer Inst. 1994 Dec 7;86(23):1785-9 [7525978.001]
  • [Cites] Br J Cancer. 1996 Nov;74(9):1445-51 [8912543.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Feb;46(2):145-54 [9135695.001]
  • [Cites] J Mol Endocrinol. 1992 Aug;9(1):31-8 [1381182.001]
  • [Cites] Breast Cancer Res Treat. 1992;22(1):21-9 [1421420.001]
  • [Cites] Endocrinology. 1993 Jan;132(1):41-52 [7678219.001]
  • [Cites] Virchows Arch. 2004 Feb;444(2):142-8 [14673647.001]
  • (PMID = 15790698.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ PMC1770626
  •  go-up   go-down


38. Kernek KM, Koch MO, Daggy JK, Juliar BE, Cheng L: The presence of benign prostatic glandular tissue at surgical margins does not predict PSA recurrence. J Clin Pathol; 2005 Jul;58(7):725-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The presence of benign prostatic glandular tissue at surgical margins does not predict PSA recurrence.
  • BACKGROUND: Serum prostate specific antigen (PSA) increases after radical prostatectomy are thought to indicate recurrent disease, although some suggest they result from benign prostatic epithelial tissue left at surgical margins.
  • AIMS: To investigate whether presence, location, and extent of benign prostatic tissue at radical prostatectomy surgical margins influence patient outcome.
  • The total length of benign prostatic tissue at the margins, measured for each location using an ocular micrometer, was obtained by summing the length of all positive sites.
  • The presence, anatomical location, and extent of benign prostatic tissue at the margin were correlated with clinicopathological characteristics and postoperative PSA increases.
  • RESULTS: Fifty five cases had benign prostatic glandular tissue at the surgical margin.
  • The most frequent location of benign prostatic tissue was the apex (40 patients).
  • Presence, anatomical location, and length of benign prostatic tissue at the margin were not significantly associated with age, preoperative PSA, prostate weight, pathological stage, tumour volume, largest tumour dimension, Gleason score, extraprostatic extension, seminal vesical invasion, tumour multifocality, perineural invasion, or PSA recurrence.
  • CONCLUSIONS: Benign prostatic tissue was frequently found in margins of apex and bladder base, but uncommon in the anterior or posterior prostate.
  • The presence of benign prostatic tissue at surgical margins had no prognostic relevance.
  • [MeSH-minor] Adult. Age Factors. Aged. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Period. Prognosis. Prostatectomy. Recurrence


39. Tun K, Celikmez RC, Okutan O, Gurcan O, Beskonakli E: Dermoid tumour of the lateral wall of the cavernous sinus. J Clin Neurosci; 2008 Jul;15(7):820-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoid tumour of the lateral wall of the cavernous sinus.
  • Congenital intracranial dermoid tumors are very rare.
  • Dermoid tumors originating from the cavernous sinus are usually interdural and thus, presentation with ophthalmoplegia is uncommon.
  • They are congenital benign tumors and are believed to originate from ectopic inclusion of epithelial cells during closure of the neural tube during embryonic development.
  • In this report, we describe the case of a dermoid cyst that was embedded in the lateral wall of the cavernous sinus and review the literature relating to related cavernous dermoid lesions.
  • [MeSH-minor] Adult. Cranial Fossa, Middle / pathology. Cranial Fossa, Middle / surgery. Dura Mater / pathology. Dura Mater / surgery. Female. Headache / etiology. Headache / pathology. Headache / physiopathology. Humans. Magnetic Resonance Imaging. Neurosurgical Procedures. Oculomotor Nerve Diseases / etiology. Oculomotor Nerve Diseases / pathology. Oculomotor Nerve Diseases / physiopathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Neurosci. 2009 Aug;16(8):1115
  • (PMID = 18462942.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


40. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry JP, Scolyer RA, Smith AN, Bali A, Vanden Bergh P, Baron-Hay S, Scott C, Fink D, Hacker NF, Sutherland RL, O'Brien PM: A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer; 2006 Mar 27;94(6):904-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A distinct molecular profile associated with mucinous epithelial ovarian cancer.
  • Mucinous epithelial ovarian cancers (MOC) are clinically and morphologically distinct from the other histological subtypes of ovarian cancer.
  • To determine the genetic basis of MOC and to identify potential tumour markers, gene expression profiling of 49 primary ovarian cancers of different histological subtypes was performed using a customised oligonucleotide microarray containing >59 000 probesets.
  • The results show that MOC express a genetic profile that both differs and overlaps with other subtypes of epithelial ovarian cancer.
  • Concordant with its histological phenotype, MOC express genes characteristic of mucinous carcinomas of varying epithelial origin, including intestinal carcinomas.
  • In particular, galectin 4 (LGALS4) was highly and specifically expressed in MOC, but expressed at lower levels in benign mucinous cysts and borderline (atypical proliferative) tumours, supporting a malignant progression model of MOC.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4722-9 [12183431.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1565-77 [12404231.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):281-92 [12604884.001]
  • [Cites] Genomics. 2003 Feb;81(2):98-104 [12620386.001]
  • [Cites] Clin Exp Metastasis. 2003;20(2):143-52 [12705635.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):985-93 [12826891.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4196-203 [12874026.001]
  • [Cites] Carcinogenesis. 2003 Aug;24(8):1291-300 [12807733.001]
  • [Cites] Exp Cell Res. 2003 Aug 15;288(2):382-9 [12915129.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):6005-12 [12955079.001]
  • [Cites] Fertil Steril. 2003 Sep;80 Suppl 2:747-54 [14505749.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7651-7 [16278384.001]
  • [Cites] Nat Genet. 2002 May;31(1):19-20 [11984561.001]
  • [Cites] J Mol Med (Berl). 1999 Oct;77(10):699-712 [10606205.001]
  • [Cites] Int J Oncol. 2000 Feb;16(2):321-5 [10639576.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):595-605 [10666389.001]
  • [Cites] J Clin Pathol. 2000 May;53(5):327-34 [10889812.001]
  • [Cites] Protein Sci. 2000 Aug;9(8):1594-600 [10975581.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5007-11 [11016619.001]
  • [Cites] Histopathology. 2001 Feb;38(2):87-95 [11207821.001]
  • [Cites] Gut. 2001 Jul;49(1):73-81 [11413113.001]
  • [Cites] Cancer Treat Res. 2002;107:247-58 [11775453.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1134-8 [11861394.001]
  • [Cites] Neoplasia. 2002 Mar-Apr;4(2):151-63 [11896570.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):41-4 [14668549.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):1045-52 [14983501.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99 [15000151.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1040-4 [15020606.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Glycoconj J. 2004;20(4):247-55 [15115909.001]
  • [Cites] Peptides. 2004 May;25(5):885-98 [15177885.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jul;23(3):200-5 [15213595.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4427-36 [15240533.001]
  • [Cites] Cancer Lett. 2004 Aug 30;212(2):253-9 [15279905.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):949-60 [15297962.001]
  • [Cites] Cancer Biol Ther. 2004 Jul;3(7):593-601 [15136761.001]
  • [Cites] Oncogene. 1997 Aug 14;15(7):799-805 [9266966.001]
  • [Cites] Hum Pathol. 1997 Aug;28(8):922-8 [9269828.001]
  • [Cites] Int J Cancer. 1998 May 29;76(5):652-8 [9610721.001]
  • [Cites] Am J Surg Pathol. 1999 Jun;23(6):617-35 [10366144.001]
  • [Cites] Eur J Cancer. 2004 Nov;40(17):2604-12 [15541961.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3587-96 [15867264.001]
  • [Cites] Pathol Int. 2005 May;55(5):231-43 [15871720.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6116-26 [16144910.001]
  • (PMID = 16508639.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Galectin 4; 0 / Genetic Markers
  • [Other-IDs] NLM/ PMC2361366
  •  go-up   go-down


41. Minelli A, Ronquist G, Carlsson L, Mearini E, Nilsson O, Larsson A: Antiprostasome antibody titres in benign and malignant prostate disease. Anticancer Res; 2005 Nov-Dec;25(6C):4399-402
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiprostasome antibody titres in benign and malignant prostate disease.
  • BACKGROUND: Prostasomes are secretory granules synthesized, stored and secreted by normal and neoplastic human prostate epithelial cells and by prostate cancer metastasis.
  • MATERIALS AND METHODS: An antiprostasome antibody ELISA was developed and used to measure serum antibody titres in 81 males with prostate cancer or benign prostate hyperplasia.
  • RESULTS: Patients with biopsy-verified prostate cancer had significantly higher antibody titres [p = 0.019 for the dominant tumour expression (first Gleason parameter) and p = 0.022 for the dominant and non-dominant form (first and second Gleason parameters)] than individuals with benign prostate hyperplasia or other benign prostate disorders.
  • [MeSH-major] Antibodies, Neoplasm / blood. Prostatic Hyperplasia / immunology. Prostatic Neoplasms / immunology. Prostatitis / immunology. Secretory Vesicles / immunology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334115.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


42. Andreadis D, Epivatianos A, Poulopoulos A, Nomikos A, Papazoglou G, Antoniades D, Barbatis C: Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. Oral Oncol; 2006 Jan;42(1):57-65
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours.
  • In the present study we analysed the expression of this molecule in salivary gland tumours.
  • Archival formalin-fixed, paraffin-embedded sections of 40 benign and 57 malignant salivary gland tumours were retrieved and retrospectively studied immunohistochemically using a polyclonal C-KIT antibody in an Envision/HRP technique.
  • In addition five samples of chronic submandibular sialadenitis, five normal minor salivary glands and parotid or submandibular gland tissue adjacent to benign tumour were also studied.
  • C-KIT expression was observed in cases of adenoid cystic, acinic cell polymorphous low grade, epithelial-myoepithelial, carcinosarcoma and basal cell adenocarcinomas, as in luminal cells of pleomorphic adenomas, in serous acinar and only in intercalated and a small number of striated ductal cells of inflammatory salivary gland tissue, whereas normal salivary lobules were generally negative except a weak positivity of intercalated cells.
  • Contrary to other reports, this study suggests that, C-KIT protein does not appear to be an exclusively specific marker for benign or malignant salivary gland neoplasms, but may be useful in differential diagnosis of adenoid cystic carcinoma from polymorphous low grade adenocarcinoma.
  • Furthermore its expression in serous acinar cells in sialadenitis and intercalated ductal cells in normal and inflammatory lesions may indicate a possible participation in pathogenesis of both neoplastic and non-neoplastic salivary gland diseases.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Adenoid Cystic / chemistry. Proto-Oncogene Proteins c-kit / analysis. Salivary Gland Neoplasms / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140564.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


43. Angouridakis N, Hytiroglou P, Markou K, Bouzakis A, Vital V: Middle ear adenoma/carcinoid tumour: a case report and review of the literature. Rev Laryngol Otol Rhinol (Bord); 2009;130(3):199-202
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for middle ear adenoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Middle ear adenoma/carcinoid tumour: a case report and review of the literature.
  • Middle ear adenoma, a rare benign tumour with glandular and neuroendocrine differentiation, originates from the epithelial lining of the middle ear.
  • CASE REPORT: We report a case of a 52-year-old woman, who presented with progressive hearing loss and fullness in the left ear for 3 months.
  • Histological examination revealed tumour cells forming gland-like and cribriform structures, as well as compact groups.
  • On immunohistochemical staining, the tumour cells were positive for epithelial (cytokeratins, epithelial membrane antigen) and neuroendocrine (neuron specific enolase, synaptophysin, chromogranin and pancreatic polypeptide) markers.
  • CONCLUSION: Middle ear adenoma is a benign tumour that is treated by complete surgical removal.
  • The immunohistochemical staining of the present case supports the suggestion that this tumour is best described by the term neuroendocrine adenoma of the middle ear.
  • [MeSH-major] Adenoma. Carcinoid Tumor. Ear Neoplasms. Ear, Middle

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20345079.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 17
  •  go-up   go-down


44. Karim RZ, Gerega SK, Yang YH, Spillane A, Carmalt H, Scolyer RA, Lee CS: p16 and pRb immunohistochemical expression increases with increasing tumour grade in mammary phyllodes tumours. Histopathology; 2010 Jun;56(7):868-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 and pRb immunohistochemical expression increases with increasing tumour grade in mammary phyllodes tumours.
  • AIMS: Control of cell cycling and proliferation is critical to the development of neoplasia and may play a role in the pathogenesis of phyllodes tumours (PTs).
  • This study aimed to evaluate the immunohistochemical expression of certain proteins from the G(1)/S transition of the cell cycle in a cohort of PTs, to determine their role in tumour pathogenesis and to identify any associations with patient outcome.
  • METHODS AND RESULTS: Sixty-five PTs (34 benign, 23 borderline and eight malignant) diagnosed at a single institution between 1990 and 2006 were analysed.
  • Expression of the following markers increased significantly with tumour grade: stromal nuclear and cytoplasmic p16 (P = 0.01 and 0.002, respectively), stromal and epithelial pRb (P = 0.000,000,06 and 0.004, respectively), and stromal and epithelial Ki67 (P = 0.03 and 0.04, respectively).
  • Epithelial pRb scores of 7 (range 0-7) were significantly associated with reduced disease-free survival (DFS) compared with scores of <7 (P = 0.0009).
  • No relationship was found between cyclin D1 expression in either the epithelium or the stroma, and grade or DFS.
  • [MeSH-major] Breast Neoplasms / metabolism. Neoplasm Proteins / metabolism. Phyllodes Tumor / metabolism. Retinoblastoma Protein / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Blotting, Western. Cyclin D1 / metabolism. Disease-Free Survival. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20497245.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / P16 protein, human; 0 / Retinoblastoma Protein; 136601-57-5 / Cyclin D1
  •  go-up   go-down


45. Gupta N, Bisht D, Agarwal AK, Sharma VK: Retrospective and prospective study of ovarian tumours and tumour-like lesions. Indian J Pathol Microbiol; 2007 Jul;50(3):525-7
MedlinePlus Health Information. consumer health - Ovarian Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective and prospective study of ovarian tumours and tumour-like lesions.
  • Two hundred and thirty three cases of ovarian tumours and tumour like lesions were studied.
  • Of these 233 cases, 96 cases were of ovarian tumours and 137 were tumour like lesions of the ovary.
  • Of the 96 cases of ovarian tumours, 72.9% were benign, 4.1% were borderline and 22.9% were malignant.
  • Histologically surface epithelial tumours were the commonest (48.8%) followed by germ cell tumours (23.9%), sex cord stromal tumours (8.3%) and metastatic tumours (2.0%).
  • Ultrasound guided FNAC done in cases of ovarian tumours showed an accuracy of 100% for malignant lesions and 100% for benign and borderline lesions when compared with histopathological diagnosis.
  • Tuberculosis constituted (2.9%) cases and was the major cause of clinical diagnostic pitfalls for cases in which a clinical diagnosis of ovarian neoplasm was made.
  • [MeSH-major] Ovarian Diseases. Ovarian Neoplasms. Peritonitis, Tuberculous
  • [MeSH-minor] Female. Humans. Incidence. Neoplasms, Germ Cell and Embryonal / epidemiology. Neoplasms, Germ Cell and Embryonal / pathology. Ovary / pathology. Prospective Studies. Retrospective Studies. Sex Cord-Gonadal Stromal Tumors / epidemiology. Sex Cord-Gonadal Stromal Tumors / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883123.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


46. Ulusan S, Bal N, Kizilkilic O, Bolat F, Yildirim S, Yildirim T, Niron EA: Case report: solid-pseudopapillary tumour of the pancreas associated with dorsal agenesis. Br J Radiol; 2005 May;78(929):441-3
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: solid-pseudopapillary tumour of the pancreas associated with dorsal agenesis.
  • Solid-pseudopapillary tumour of the pancreas is a rare benign or low-grade malignant epithelial tumour; its association with pancreatic dorsal agenesis has been reported only once before.
  • We present the radiological and histological findings of a case of pancreatic solid-pseudopapillary tumour associated with total pancreatic dorsal agenesis.
  • Radiological findings showed absence of the dorsal pancreas and an 8 cm x 6 cm diameter tumour arising from the head of the pancreas.
  • She underwent successful complete resection of the tumour.
  • Histopathology revealed a diagnosis of solid-pseudopapillary tumour.

  • Genetic Alliance. consumer health - Pancreas agenesis, dorsal.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15845940.001).
  • [ISSN] 0007-1285
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


47. Miyamoto T, Hagari Y, Inoue S, Watanabe T, Yoshino T: Axillary apocrine carcinoma with benign apocrine tumours: a case report involving a pathological and immunohistochemical study and review of the literature. J Clin Pathol; 2005 Jul;58(7):757-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Axillary apocrine carcinoma with benign apocrine tumours: a case report involving a pathological and immunohistochemical study and review of the literature.
  • AIMS/METHODS: Because benign apocrine tumours may be precursors of cancer, this case was investigated immunohistochemically and histologically, and a literature (English and Japanese) review undertaken of cases with coexistent malignant and benign apocrine tumours in the axilla to elucidate the relation between apocrine carcinoma and benign apocrine tumours.
  • RESULTS: Only four cases of axillary apocrine carcinoma with benign apocrine tumours were identified in the literature.
  • In each case, benign apocrine hyperplasia was situated within and surrounding the adenocarcinomatous nests.
  • Staining for epithelial membrane antigen revealed three patterns:.
  • (1) poorly differentiated tumour cells showing strong cytoplasmic staining;.
  • CONCLUSIONS: All five apocrine carcinomas with benign apocrine tumours occurred in elderly Japanese men who had bilateral benign apocrine tumours even if affected by unilateral axillary apocrine carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 1999 Apr;22(2):131-5 [10199445.001]
  • [Cites] J Dermatol. 1997 Aug;24(8):535-8 [9301148.001]
  • [Cites] Pathol Res Pract. 2001;197(6):419-25 [11432669.001]
  • [Cites] Pathol Int. 2002 Feb;52(2):169-73 [11940224.001]
  • [Cites] J Pathol. 2002 Dec;198(4):458-67 [12434415.001]
  • [Cites] J Pathol. 2003 Jan;199(1):1-3 [12474219.001]
  • [Cites] J Dermatol. 2003 Jan;30(1):72-5 [12598714.001]
  • [Cites] Histopathology. 1989 Apr;14(4):409-16 [2544501.001]
  • [Cites] Acta Pathol Jpn. 1990 Jun;40(6):431-4 [2203231.001]
  • [Cites] Am J Surg Pathol. 1990 Oct;14(10):939-47 [1698341.001]
  • [Cites] Acta Pathol Jpn. 1991 Dec;41(12):927-32 [1785351.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(4):323-30 [1384227.001]
  • [Cites] Cancer. 1993 Jan 15;71(2):375-81 [7678545.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):832-6 [8037297.001]
  • [Cites] Am J Dermatopathol. 2001 Feb;23(1):50-7 [11176053.001]
  • (PMID = 15976347.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 18
  • [Other-IDs] NLM/ PMC1770727
  •  go-up   go-down


48. Sorenmo KU, Kristiansen VM, Cofone MA, Shofer FS, Breen AM, Langeland M, Mongil CM, Grondahl AM, Teige J, Goldschmidt MH: Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence. Vet Comp Oncol; 2009 Sep;7(3):162-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence.
  • This study describes the clinical and histopathological findings in dogs with mammary gland tumours, and compares the histopathological and clinical evidence consistent with progression from benign to malignant to human breast cancer epidemiology.
  • Clinical and histopathological data on 90 female dogs with 236 tumours was included.
  • Dogs with malignant tumours were significantly older than dogs with benign tumours (9.5 versus 8.5 years), P = 0.009.
  • Malignant tumours were significantly larger than benign tumours (4.7 versus 2.1 cm), P = 0.0002.
  • Sixty-six percent had more than one tumour, and evidence of histological progression was noted with increasing tumour size.
  • Dogs with malignant tumours were significantly more likely to develop new primary tumours than dogs with benign tumours, P = 0.015.
  • These findings suggest that canine mammary tumours progress from benign to malignant; malignant tumours may be the end stage of a histological continuum with clinical and histopathological similarities to human breast carcinogenesis.
  • [MeSH-major] Dog Diseases / pathology. Mammary Neoplasms, Animal / pathology. Mixed Tumor, Malignant / veterinary. Neoplasms / veterinary
  • [MeSH-minor] Adenocarcinoma / veterinary. Adenoma / veterinary. Animals. Carcinoma / veterinary. Dogs. Female. Neoplasms, Complex and Mixed / pathology. Neoplasms, Complex and Mixed / veterinary. Neoplasms, Glandular and Epithelial / veterinary. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19691645.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


49. Mhawech-Fauceglia P, Saxena R, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, Penetrante R: Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis. J Clin Pathol; 2007 Jun;60(6):709-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.
  • However, its expression in other tumour types is not fully explored.
  • AIMS AND METHODS: To determine Pax-5 expression in other tumour types, immunohistochemistry was performed on 3758 benign and malignant tumours using multiple tumour microarrays, as well as on whole sections.
  • CONCLUSION: Despite its expression in a small subset of malignancies of epithelial origin, Pax-5 is still a good and reliable immunomarker in diagnosing B-NHL, HL and neuroendocrine carcinomas.
  • [MeSH-major] B-Cell-Specific Activator Protein / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Hodgkin Disease / diagnosis. Hodgkin Disease / metabolism. Humans. Immunoenzyme Techniques. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / metabolism. Neoplasm Proteins / metabolism. Protein Array Analysis / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 2001 Jun;14(6):779-90 [11420047.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):687-92 [15832095.001]
  • [Cites] Trends Genet. 2002 Jan;18(1):41-7 [11750700.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1343-50 [12360049.001]
  • [Cites] Int Urol Nephrol. 2002-2003;34(4):495-501 [14577491.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):994-1000 [14608532.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):1839-46 [15155532.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):721-7 [15491968.001]
  • [Cites] Mech Dev. 1992 Nov;39(1-2):29-39 [1283313.001]
  • [Cites] Genomics. 1993 Dec;18(3):705-8 [7508415.001]
  • [Cites] C R Acad Sci III. 1995 Jan;318(1):57-66 [7757805.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5709-13 [7777574.001]
  • [Cites] Genes Dev. 1997 Feb 15;11(4):476-91 [9042861.001]
  • [Cites] J Immunol. 1997 Apr 1;158(7):3197-204 [9120274.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5703-8 [9159136.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Clin Cancer Res. 1995 Feb;1(2):207-14 [9815975.001]
  • [Cites] Gen Physiol Biophys. 1998 Sep;17(3):211-24 [9834843.001]
  • [Cites] BJU Int. 1999 Jun;83(9):1039-44 [10368252.001]
  • [Cites] Nature. 1999 Oct 7;401(6753):556-62 [10524622.001]
  • [Cites] Int J Cancer. 2001 Aug 15;93(4):459-67 [11477548.001]
  • (PMID = 16837628.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / PAX5 protein, human
  • [Other-IDs] NLM/ PMC1955074
  •  go-up   go-down


50. Ge MJ, Shi D, Wu QC, Wang M, Li LB: Observation of circulating tumour cells in patients with non-small cell lung cancer by real-time fluorescent quantitative reverse transcriptase-polymerase chain reaction in peroperative period. J Cancer Res Clin Oncol; 2006 Apr;132(4):248-56
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Observation of circulating tumour cells in patients with non-small cell lung cancer by real-time fluorescent quantitative reverse transcriptase-polymerase chain reaction in peroperative period.
  • Additionally, the ten patients with benign lung disease served as control subjects undergoing surgical resection.
  • Surprisingly, circulating epithelial cells were detected in two patients resected for benign lung disease. (2) The CEA diagnostic test: the level of CEA mRNA ascended continuously within this period.
  • Both patients with benign lung disease served as control subjects undergoing surgical resection and the volunteers were negative.
  • CONCLUSIONS: A considerable proportion of patients who appear to have resectable NSCLC might be regarded as having systemic disease, which is often undetectable by current tumour staging method.
  • In terms of a marker used for the NSCLC patients who undergo operation, CEA is more suitable than CK19.
  • The CK19-expressing epithelial cells are released intraoperatively into the circulation, meanwhile CEA-expressing tumour cells are disseminated mostly postoperatively.
  • Surgical manipulation could promote the release of tumour cells into the bloodstream, but the ligation of pulmonary vein before the ligation of the pulmonary artery may partly prevent such release during surgery.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16320073.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / RNA, Messenger
  •  go-up   go-down


51. Tokés AM, Kulka J, Paku S, Szik A, Páska C, Novák PK, Szilák L, Kiss A, Bögi K, Schaff Z: Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res; 2005;7(2):R296-305
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study.
  • INTRODUCTION: We compared levels of protein and mRNA expression of three members of the claudin (CLDN) family in malignant breast tumours and benign lesions.
  • CLDN1 was present in the membrane of normal duct cells and in some of the cell membranes from ductal carcinoma in situ, and was frequently observed in eight out of nine areas of apocrine metaplasia, whereas invasive tumours were negative for CLDN1 or it was present in a scattered distribution among such tumour cells (in 36/39 malignant tumours).
  • However, CLDN4 was highly positive in normal epithelial cells and was decreased or absent in 17 out of 21 ductal carcinoma grade 1, in special types of breast carcinoma (mucinous, papillary, tubular) and in areas of apocrine metaplasia.
  • CLDN1 mRNA was downregulated by 12-fold in the sample (tumour) group as compared with the control group using GAPDH as the reference gene.
  • CLDN3 and CLDN4 mRNA exhibited no difference in expression between invasive tumours and surrounding tissue.
  • [MeSH-major] Breast Diseases / genetics. Breast Neoplasms / genetics. Membrane Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Claudin-1. Claudin-3. Claudin-4. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Polymerase Chain Reaction. RNA, Messenger / analysis. RNA, Messenger / biosynthesis. Tight Junctions

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cell Biol. 1999 Dec;78(12):849-55 [10669103.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):48350-5 [11602598.001]
  • [Cites] Gastroenterology. 2001 Feb;120(2):411-22 [11159882.001]
  • [Cites] J Cell Biol. 2002 Mar 18;156(6):1099-111 [11889141.001]
  • [Cites] J Cell Physiol. 2002 Apr;191(1):60-8 [11920682.001]
  • [Cites] Oncol Res. 2001;12(11-12):469-76 [11939410.001]
  • [Cites] Nucleic Acids Res. 2002 May 1;30(9):e36 [11972351.001]
  • [Cites] Prog Biophys Mol Biol. 2003 Jan;81(1):1-44 [12475568.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):2021-33 [12673207.001]
  • [Cites] Int J Mol Med. 2003 Jun;11(6):683-9 [12736707.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Jul;29(1):62-70 [12600828.001]
  • [Cites] Arch Androl. 2003 Jul-Aug;49(4):271-9 [12851029.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2567-75 [12855632.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6265-71 [14559813.001]
  • [Cites] J Cell Sci. 1979 Feb;35:393-402 [422677.001]
  • [Cites] FEBS Lett. 1987 Sep 14;221(2):359-64 [3114004.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] J Cell Physiol. 1992 Jul;152(1):35-47 [1618921.001]
  • [Cites] J Cell Biol. 1998 Apr 20;141(2):397-408 [9548718.001]
  • [Cites] J Cell Biol. 1998 Jun 29;141(7):1539-50 [9647647.001]
  • [Cites] J Cell Biol. 1998 Oct 19;143(2):391-401 [9786950.001]
  • [Cites] Gene. 1999 Jan 21;226(2):285-95 [9931503.001]
  • [Cites] Trends Cell Biol. 1999 Jul;9(7):268-73 [10370242.001]
  • [Cites] Carcinogenesis. 1999 Aug;20(8):1425-31 [10426787.001]
  • [Cites] Curr Biol. 1999 Sep 23;9(18):1035-8 [10508613.001]
  • [Cites] J Cell Biol. 1999 Oct 4;147(1):195-204 [10508866.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Aug;279(2):G250-4 [10915631.001]
  • [Cites] Hum Genet. 2000 Sep;107(3):249-56 [11071387.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Endocrinology. 2001 Feb;142(2):854-63 [11159859.001]
  • [Cites] J Clin Invest. 2001 May;107(10):1319-27 [11375422.001]
  • [Cites] Clin Chem Lab Med. 2000 Feb;38(2):171-7 [10834406.001]
  • (PMID = 15743508.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / Claudin-1; 0 / Claudin-3; 0 / Claudin-4; 0 / Membrane Proteins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC1064136
  •  go-up   go-down


52. Zhong W, Peng J, He H, Wu D, Han Z, Bi X, Dai Q: Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clin Invest Med; 2008;31(1):E8-E15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.
  • The purpose of this study is to investigate the expression levels of Ki-67 and PCNA in prostate cancer (PCa) and benign prostatic hyperplasia (BPH) and their potential on the early diagnosis of PCa.
  • METHODS: Human prostate cancer cell lines LNCaP and PC-3, human normal prostate epithelial cell line HuPEC, tissues from patients with PCa (121 cases) and BPH (45) and 36 normal cases were examined for the expression of Ki-67 and PCNA by Reverse Transcription-Polymerase Chain Reaction (RT-PCR).
  • Compared with BPH, the ratio of Ki-67 and PCNA expressed in tumour tissue was increased (P < 0.05).
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Gene Expression Regulation, Neoplastic. Ki-67 Antigen / biosynthesis. Proliferating Cell Nuclear Antigen / biosynthesis. Prostatic Hyperplasia / metabolism. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Cell Line, Tumor. Humans. Male. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction


53. Patrikainen L, Porvari K, Kurkela R, Hirvikoski P, Soini Y, Vihko P: Expression profiling of PC-3 cell line variants and comparison of MIC-1 transcript levels in benign and malignant prostate. Eur J Clin Invest; 2007 Feb;37(2):126-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiling of PC-3 cell line variants and comparison of MIC-1 transcript levels in benign and malignant prostate.
  • BACKGROUND: The mechanisms behind prostate cancer progression are largely unknown, but macrophage inhibitory cytokine 1 (MIC-1) has been suggested to be involved in tumour dissemination in vivo due to its reductive effect on cell adhesion.
  • MATERIALS AND METHODS: We used two PC-3 prostate cancer epithelial cell line variants as tools to screen for gene expression differences during prostate cancer progression by cDNA microarray analysis.
  • MIC-1 expression was studied by in situ hybridization in archival patient specimens containing benign and malignant prostatic tissue.
  • However, MIC-1 transcripts were detected in benign tissue areas, especially in specimens containing prostate cancer with Gleason sum scores of 5-8.
  • A significant inverse correlation (Spearman's rho correlation coefficient -0.928**) was observed between the ratio of cancerous to benign MIC-1 expression levels and Gleason scores.
  • The transcript level of the MIC-1 gene in histologically benign tissue seems to approach that in paired cancer tissue concomitant with an increasing Gleason score.
  • [MeSH-minor] Blotting, Northern. Cell Adhesion / physiology. Cell Line, Tumor. Epithelial Cells / metabolism. Gene Expression. Growth Differentiation Factor 15. Humans. Male. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17217378.001).
  • [ISSN] 0014-2972
  • [Journal-full-title] European journal of clinical investigation
  • [ISO-abbreviation] Eur. J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / GDF15 protein, human; 0 / Growth Differentiation Factor 15; 0 / RNA, Messenger
  •  go-up   go-down


54. Song DE, Kim YM, Gong G: Cytomorphological changes after ultrasound-guided percutaneous ethanol injection in benign thyroid nodules. Cytopathology; 2009 Jun;20(3):183-7
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphological changes after ultrasound-guided percutaneous ethanol injection in benign thyroid nodules.
  • OBJECTIVE: To characterize the cytomorphological changes after percutaneous ethanol injection (PEI) in benign thyroid nodules, we compared the cytological features of fine needle aspiration cytology (FNAC) samples before and after PEI.
  • The following cytological features were evaluated by two pathologists: cellularity of follicular epithelial cells, background, cellular pleomorphism, nuclear/cytoplasmic (N/C) ratio, chromatin pattern, presence of nucleoli, macrophages, multinucleated giant cells, and mitosis.
  • CONCLUSIONS: Necrotic background and presence of multinucleated giant cells are indicative of tissue damage caused by PEI in the FNAC specimens of benign thyroid nodules.
  • In contrast to other modalities including chemotherapy or radiation treatment for malignant tumour, no unusual cytological change is observed after PEI.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18476990.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


55. Kuźbicki L, Gajo B, Chwirot BW: Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions. Melanoma Res; 2006 Jun;16(3):235-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions.
  • It is thought that enhanced expression of lysosome-associated membrane protein-1 in tumour cells may promote invasion by influencing both adhesion to extracellular matrix and perhaps also binding to endothelial cells.
  • The present study was aimed at examining levels of lysosome-associated membrane protein-1 in human melanomas and benign pigmented lesions to evaluate whether this protein might be considered a potential molecular marker of melanoma progression.
  • The expression of lysosome-associated membrane protein-1 was for the first time determined immunohistochemically in formalin-fixed paraffin-embedded specimens comprising 42 primary cutaneous melanomas, 15 lymph node melanoma metastases (11 correlated with primary tumours), three melanoma recurrences (correlated with both primary and metastatic melanomas), 27 nevi and four epithelial tumours (two seborrhoeic keratoses and two basal cell carcinomas).
  • [MeSH-minor] Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Immunohistochemistry. Lymphatic Metastasis. Neoplasm Recurrence, Local / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16718270.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Lysosomal-Associated Membrane Protein 1
  •  go-up   go-down


56. Jakab C, Rusvai M, Szabó Z, Szabára A, Kulka J: Expression of the claudin-4 molecule in benign and malignant canine hepatoid gland tumours. Acta Vet Hung; 2009 Dec;57(4):463-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the claudin-4 molecule in benign and malignant canine hepatoid gland tumours.
  • Claudins are integral membrane proteins of the tight junction structures expressed by epithelial and endothelial cells.
  • Claudin-4 was detected as a well-localised linear circumferential membranous staining pattern of epithelial cells (mature hepatoid cells) in normal hepatoid glands, perianal gland hyperplasias and adenomas.
  • These results suggest that low claudin-4 expression in epitheliomas is a molecular characteristic indicative of increasing cellular disorientation, detachment motility and invasion by tumour cells, and claudin-4 seems to be helpful in distinguishing undifferentiated carcinomas from differentiated carcinomas and epitheliomas of the hepatoid gland.
  • In addition, claudin-4 can help distinguish epithelioma from differentiated carcinoma of the canine hepatoid gland.
  • [MeSH-major] Anal Gland Neoplasms / metabolism. Dog Diseases / metabolism. Gene Expression Regulation, Neoplastic / physiology. Membrane Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19897451.001).
  • [ISSN] 0236-6290
  • [Journal-full-title] Acta veterinaria Hungarica
  • [ISO-abbreviation] Acta Vet. Hung.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Claudin-4; 0 / Membrane Proteins
  •  go-up   go-down


57. Oxenius I, Vacirca F: [A rare case of fibroepithelial polyp of the proximal urethra in a young woman]. Urologia; 2008 Jul-Sep;75(3):193-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibroepithelial polyps are benign epithelial tumours which are rare in adults.
  • We report a case of a twenty-seven-year-old woman, presenting with painless terminal gross haematuria, affected by a neoplasm located in the proximal urethra near the bladder neck.
  • Endoscopic image of the tumour and histopatological details are shown.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086351.001).
  • [ISSN] 0391-5603
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


58. Nuñez C, Cansino JR, Bethencourt F, Pérez-Utrilla M, Fraile B, Martínez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M: TNF/IL-1/NIK/NF-kappa B transduction pathway: a comparative study in normal and pathological human prostate (benign hyperplasia and carcinoma). Histopathology; 2008 Aug;53(2):166-76
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TNF/IL-1/NIK/NF-kappa B transduction pathway: a comparative study in normal and pathological human prostate (benign hyperplasia and carcinoma).
  • AIMS: Tumour necrosis factor (TNF)-alpha induces death or cell proliferation by activation of nuclear factor (NF)-kappaB, also activated by interleukin (IL)-1 alpha.
  • The aim was to investigate upstream and downstream components of NIK transduction pathway in normal (NP), benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN) and prostatic carcinoma (PC).
  • In NP, the cytoplasm of epithelial cells was intensely immunoreactive to IL-1 receptor-associated kinase (IRAK), TNF receptor-associated factor (TRAF)-6, NF-kappaB inducing kinase (NIK), I kappa kappa alpha/beta, I kappaB alpha and p-I kappaB; weakly to NF-kappaB-p50; and negative to NF-kappaB-p65.
  • [MeSH-major] Carcinoma / enzymology. Interleukin-1 / physiology. NF-kappa B / physiology. Prostatic Hyperplasia / enzymology. Prostatic Neoplasms / enzymology. Protein-Serine-Threonine Kinases / physiology. Signal Transduction / physiology. Tumor Necrosis Factor-alpha / physiology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18752500.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukin-1; 0 / NF-kappa B; 0 / Tumor Necrosis Factor-alpha; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.25 / NF-kappa B kinase
  •  go-up   go-down


59. Gaisa NT, Henkel C, Knüchel R: Tumour node metastasis staging of bladder cancer: prognosis versus pitfalls. Curr Opin Urol; 2010 Sep;20(5):398-403
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour node metastasis staging of bladder cancer: prognosis versus pitfalls.
  • PURPOSE OF REVIEW: The WHO classification of urothelial cancer in 2004 has made changes based on the insights of molecular genetics, indicating bladder cancer with entities that are genetically stable versus those that are genetically instable.
  • This combined with molecular data will lead to a more clear-cut distinction between benign and malignant and possibly to another change in terminology with higher concordance to other epithelial tumours.
  • SUMMARY: Recent data mainly support the concept of the WHO 2004 classification of bladder cancer.
  • We are optimistic that an even more clear-cut distinction between benign recurring, nonprogressing tumours and more aggressive tumours will enable us to focus and limit chemotherapy.
  • [MeSH-major] Lymph Nodes / pathology. Neoplasm Staging. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Humans. Lymphatic Metastasis. Molecular Diagnostic Techniques. Neoplasm Invasiveness. Predictive Value of Tests. Prognosis. Reproducibility of Results

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20625299.001).
  • [ISSN] 1473-6586
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


60. Madrid C, Aziza J, Hlali A, Bouferrache K, Abarca M: Melanotic neuroectodermal tumour of infancy: a case report and review of the aetiopathogenic hypotheses. Med Oral Patol Oral Cir Bucal; 2010 Sep;15(5):e739-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanotic neuroectodermal tumour of infancy: a case report and review of the aetiopathogenic hypotheses.
  • The case of a 2-month-old healthy infant without relevant medical history.
  • The patient was referred due to the aggravation of a swelling occupying the left half of the anterior maxilla.
  • The tooth buds of 6.1 and 6.2 were closely related to the tumour and so were removed.
  • The pathology of the lesion confirmed a melanotic neuroectodermal tumour of infancy.
  • The melanotic neuroectodermal tumour of infancy (MNTI) has been described as a rare benign pigmented painless swelling that usually occurs in the anterior region of the maxilla and in the incisor region.
  • According to Krompecher this tumour derives from epithelial nests evolved at the time of embryonic fusion of the facial processes.
  • It has also been suggested that the tumour arises from the retinal anlage by a pinching-off process of neuroepithelium during the formation of embryonic eye.
  • More recently, the presence of high levels of vanillylmandelic acid suggest a neural origin of the tumour.
  • [MeSH-major] Maxillary Neoplasms. Neuroectodermal Tumor, Melanotic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173714.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  •  go-up   go-down


61. Reis-Filho JS, Steele D, Di Palma S, Jones RL, Savage K, James M, Milanezi F, Schmitt FC, Ashworth A: Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod Pathol; 2006 Feb;19(2):307-19
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue.
  • NGFR is reported to act as a tumour suppressor, negatively regulating cell growth and proliferation.
  • NGFR expression was immunohistochemically analysed in normal breast tissue and in 140 benign, biphasic and preinvasive breast lesions, in 22 tumours with myoepithelial differentiation and in two cohorts of breast cancer patients: a series of 245 invasive breast carcinomas studied with tissue microarrays and 37 high-grade invasive ductal carcinomas with basal-like immunophenotype.
  • Myoepithelial cells of benign proliferations and pre-invasive lesions were consistently positive for NGFR.
  • NGFR expression in invasive tumours significantly correlated with that of cytokeratins 5/6 (P<0.05), 14 (P<0.0001) and 17 (P<0.0005) and EGFR (P<0.0001) and displayed an inverse correlation with oestrogen and progesterone receptors (both, P<0.0001).
  • [MeSH-minor] Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Humans. Immunohistochemistry. Keratin-14. Keratin-5. Keratin-6. Keratins / analysis. Myoepithelioma / metabolism. Myoepithelioma / pathology. Neoplasm Invasiveness. Receptors, Estrogen / analysis. Receptors, Nerve Growth Factor. Receptors, Progesterone / analysis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424897.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRT14 protein, human; 0 / KRT5 protein, human; 0 / KRT6A protein, human; 0 / KRT6B protein, human; 0 / KRT6C protein, human; 0 / Keratin-14; 0 / Keratin-5; 0 / Keratin-6; 0 / NGFR protein, human; 0 / Nerve Tissue Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Growth Factor; 0 / Receptors, Nerve Growth Factor; 0 / Receptors, Progesterone; 68238-35-7 / Keratins
  •  go-up   go-down


62. Wozny W, Schroer K, Schwall GP, Poznanović S, Stegmann W, Dietz K, Rogatsch H, Schaefer G, Huebl H, Klocker H, Schrattenholz A, Cahill MA: Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: cancer association of annexin A3. Proteomics; 2007 Jan;7(2):313-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: cancer association of annexin A3.
  • A differential quantitative protein expression study, comparing matched prostate cancerous and benign tissues from 31 patients, revealed proteins newly associated with prostate cancer.
  • The most differentially abundant proteins between cancer and benign samples were isopeptidase T, serum amyloid P (SAP), annexin A3 (ANXA3) and mitochondrial enoyl coenzyme-A hydratase.
  • SAP is restricted to stroma in healthy tissue, and the lower abundance in tumours may be explained by the reduced stromal content.
  • ANXA3 is present in healthy epithelial cells, exhibits strong staining in precancerous prostatic intraepithelial neoplasia, and is relatively less abundant in individual tumour cells of increasing Gleason pattern (GP), despite exhibiting higher overall tissue abundance in tumours.
  • Strongly staining single cells, possibly phagocytes, were interspersed in highly dedifferentiated GP5 tumour areas among tumour cells without measurable ANXA3.
  • Local recurrent androgen ablation therapy-resistant tumours exhibit heterogenous low levels of ANXA3 staining.
  • Results are discussed focussing on the potential implications for tumour tissues.
  • [MeSH-major] Annexin A3 / metabolism. Biomarkers, Tumor. Prostatic Hyperplasia / metabolism. Prostatic Neoplasms / metabolism. Radioisotopes


63. Kizawa K, Toyoda M, Ito M, Morohashi M: Aberrantly differentiated cells in benign pilomatrixoma reflect the normal hair follicle: immunohistochemical analysis of Ca-binding S100A2, S100A3 and S100A6 proteins. Br J Dermatol; 2005 Feb;152(2):314-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrantly differentiated cells in benign pilomatrixoma reflect the normal hair follicle: immunohistochemical analysis of Ca-binding S100A2, S100A3 and S100A6 proteins.
  • BACKGROUND: Pilomatrixoma is a common benign cutaneous tumour containing differentiated hair matrix cells.
  • This tumour is mainly composed of basophilic, transitional, shadow and squamoid cells.
  • OBJECTIVES: To characterize the disordered epithelial elements of pilomatrixoma by localizing S100A2, S100A3 and S100A6 proteins.
  • RESULTS: Tissue-specific distribution of the S100 proteins investigated was preserved in the morphologically disordered tumour tissues.
  • CONCLUSIONS: The epithelial elements of pilomatrixoma can be characterized using S100 proteins as biochemical markers.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Hair Diseases / metabolism. Pilomatrixoma / metabolism. S100 Proteins / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Basophils / metabolism. Calcium-Binding Proteins / metabolism. Cell Cycle Proteins / metabolism. Cell Differentiation. Chemotactic Factors / metabolism. Hair Follicle / metabolism. Humans. Neoplasm Proteins / metabolism. Skin / metabolism

  • Genetic Alliance. consumer health - Pilomatrixoma.
  • MedlinePlus Health Information. consumer health - Hair Problems.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15727645.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Cell Cycle Proteins; 0 / Chemotactic Factors; 0 / Neoplasm Proteins; 0 / S100 Proteins; 0 / S100A2 protein, human; 0 / S100A3 protein, human; 105504-00-5 / S100A6 protein, human
  •  go-up   go-down


64. Zhang GY, Ahmed N, Riley C, Oliva K, Barker G, Quinn MA, Rice GE: Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. Br J Cancer; 2005 Jan 17;92(1):113-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma.
  • Previous studies have demonstrated the expression of PPARgamma in several tumours including colon, breast, bladder, prostate, lung and stomach.
  • This study demonstrates the relative expression of PPARgamma in normal ovaries and different pathological grades of ovarian tumours of serous, mucinous, endometrioid, clear cell and mixed subtypes.
  • A total of 56 ovarian specimens including 10 normal, eight benign, 10 borderline, seven grade 1, nine grade 2 and 12 grade 3 were analysed using immunohistochemistry.
  • Out of eight benign and 10 borderline tumours, only one tumour in each group showed weak cytoplasmic PPARgamma expression.
  • An altered staining pattern of PPARgamma was observed in high-grade ovarian tumours with PPARgamma being mostly localized in the nuclei with little cytoplasmic immunoreactivity.
  • On the other hand, predominant cytoplasmic staining was observed in lower-grade tumours.
  • Significantly increased PPARgamma immunoreactivity was observed in malignant ovarian tumours (grade 1, 2 and 3) compared to benign and borderline tumours (chi2 = 48.80, P < 0.001).
  • Western blot analyses showed significant elevation in the expression of immunoreactive PPARgamma in grade 3 ovarian tumours compared with that of normal ovaries and benign ovarian tumours (P < 0.01).

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):752-7 [12866036.001]
  • [Cites] Oncogene. 2003 Jun 19;22(25):3888-900 [12813462.001]
  • [Cites] Mol Cell Biol. 2003 Sep;23(17):6159-73 [12917338.001]
  • [Cites] Oncogene. 2003 Aug 21;22(35):5446-50 [12934104.001]
  • [Cites] Arch Pathol Lab Med. 2003 Sep;127(9):1121-3 [12946234.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4440-5 [12970322.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4627-35 [14555539.001]
  • [Cites] Minerva Ginecol. 2003 Aug;55(4):297-314 [14581855.001]
  • [Cites] Nat Immunol. 2004 Jan;5(1):104-12 [14691478.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2004 Feb;286(2):E201-7 [14701665.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Mar 5;315(2):497-501 [14766236.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1181-9 [14871855.001]
  • [Cites] Gut. 2004 Mar;53(3):331-8 [14960510.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):355-66 [14764655.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(8):3430-44 [15060163.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2415-20 [15073119.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7355-9 [8041794.001]
  • [Cites] Eur J Biochem. 1996 Jul 1;239(1):1-7 [8706692.001]
  • [Cites] Curr Opin Cell Biol. 1998 Jun;10(3):384-91 [9640540.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1053-7 [9734399.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6 [10097144.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):2011-7 [10213514.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jan;19(1):7-15 [10638449.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Mutat Res. 2000 Mar 17;448(2):139-51 [10725468.001]
  • [Cites] Nature. 2000 May 25;405(6785):421-4 [10839530.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3241-8 [10955810.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10990-5 [10984506.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5494-8 [11034093.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1394-400 [11044367.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13275-80 [11087869.001]
  • [Cites] Toxicol Lett. 2000 Dec 20;118(1-2):79-86 [11137312.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2598-603 [11226285.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):483-90 [11228540.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5307-10 [11431375.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Oct;127(10):1253-9 [11587608.001]
  • [Cites] Annu Rev Med. 2002;53:409-35 [11818483.001]
  • [Cites] J Biol Chem. 2002 May 17;277(20):17830-5 [11884400.001]
  • [Cites] Lung Cancer. 2002 Jun;36(3):249-55 [12009233.001]
  • [Cites] Mol Hum Reprod. 2002 Jun;8(6):574-9 [12029076.001]
  • [Cites] Invest New Drugs. 2002 May;20(2):195-200 [12099579.001]
  • [Cites] Jpn J Clin Oncol. 2002 Jul;32(7):238-43 [12324573.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):597-602 [12594814.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):11945-53 [12551936.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3198-203 [12912973.001]
  • (PMID = 15583697.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / PPAR gamma
  • [Other-IDs] NLM/ PMC2361744
  •  go-up   go-down


65. Gao GL, Liu LD, Zou XS, Chen WX: [Expression of KiSS-1, matrix metalloproteinase-9, nuclear factor-kappaBp65 in ovarian tumour]. Zhonghua Fu Chan Ke Za Zhi; 2007 Jan;42(1):34-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of KiSS-1, matrix metalloproteinase-9, nuclear factor-kappaBp65 in ovarian tumour].
  • OBJECTIVE: To investigate the expression and correlation of KiSS-1, matrix metalloproteinase-9 (MMP-9) and nuclear factor (NF)-kappaBp65 proteins in primary epithelial ovarian tumors.
  • METHODS: Expression of KiSS-1, MMP-9, NF-kappaBp65 proteins in primary ovarian epithelial tumors (malignant n = 50, borderline tumor n = 20, benign adenoma n = 20, normal tissue n = 10) was evaluated by immunohistochemical staining.
  • RESULTS: Expression of metastin protein in primary epithelial ovarian cancers was significantly higher than that in ovarian benign adenoma (P < 0.05) and normal tissues (P < 0.05).
  • Expression of metastin protein in ovarian borderline tumors was significantly higher than that in normal tissues (P < 0.05).
  • However, Metastin protein expression was not correlated with different histological classifications (P > 0.05), differentiation grade (P > 0.05) and International Federation of Gynecology and Obstetrics (FIGO) stage (P > 0.05).
  • MMP-9 protein was positive in 68% (34/50) of the epithelial ovarian cancers, significantly higher than that in normal tissues (20%, 2/10; P < 0.05).
  • NF-kappaBp65 protein was positive in 72% (36/50) of the epithelial ovarian cancers, significantly higher than that in ovarian benign adenoma (30%, 6/20; P < 0.05) and normal tissues (10%, 1/10; P < 0.05).
  • The expression of MMP-9 protein in epithelial ovarian cancer was significantly correlated with FIGO stage (P < 0.05) and lymph node metastasis (P < 0.05).
  • The expression of NF-kappaBp65 protein in epithelial ovarian cancer was significantly correlated with FIGO stage (P < 0.05), differentiation grade (P < 0.05) and lymph node metastasis (P < 0.05).
  • CONCLUSION: The results indicate that KiSS-1 plays some role in suppression of the metastasis of ovarian epithelial cancers, which may be through inhibiting the expression of MMP-9 and NF-kappaBp65.
  • [MeSH-major] Matrix Metalloproteinase 9 / biosynthesis. Ovarian Neoplasms / metabolism. Transcription Factor RelA / biosynthesis. Tumor Suppressor Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Immunohistochemistry. Kisspeptins. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17331419.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / KISS1 protein, human; 0 / Kisspeptins; 0 / Transcription Factor RelA; 0 / Tumor Suppressor Proteins; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


66. Faleiro-Rodrigues C, Macedo-Pinto IM, Maia SS, Vieira RH, Lopes CS: Biological relevance of E-cadherin-catenin complex proteins in primary epithelial ovarian tumours. Gynecol Obstet Invest; 2005;60(2):75-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological relevance of E-cadherin-catenin complex proteins in primary epithelial ovarian tumours.
  • This study analysed the biological relevance of E-cadherin, alpha-catenin, beta-catenin and gamma-catenin immunoexpression pattern (reduced vs. preserved phenotype) in epithelial ovarian tumours.
  • Immunohistochemistry was used to evaluate the expression of these proteins in 154 epithelial ovarian tumours, consisting of 17 benign, 33 borderline and 104 malignant tumours.
  • In borderline tumours, the immunoexpression pattern of E-cadherin (p = 0.014) and alpha-catenin (p = 0.030) associated with histological type.
  • In malignant tumours, the immunoexpression pattern of E-cadherin was related with histological type (p = 0.001).
  • The immunoexpression pattern of beta-catenin associated with histological type and tumour differentiation (p = 0.005, p = 0.025, respectively).
  • The preserved phenotype of E-cadherin was most frequently observed in mucinous tumours, whereas reduced E-cadherin was most frequently observed in serous tumours.
  • Although the reduced phenotype was the most frequent immunoexpression observed for all proteins of the E-cadherin-catenin complex in epithelial ovarian tumours, only beta-catenin showed a significant difference between benign, borderline and malignant tumours (p = 0.045), since borderline and malignant tumours most frequently showed the reduced phenotype.
  • The immunohistochemical profile of beta-catenin was shown to be of biological relevance: reduced beta-catenin was correlated with loss of tumour differentiation and serous carcinomas that are known to depict aggressive biological behaviour in epithelial ovarian tumours.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15785075.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / CTNNA1 protein, human; 0 / CTNNB1 protein, human; 0 / Cadherins; 0 / Cytoskeletal Proteins; 0 / Desmoplakins; 0 / JUP protein, human; 0 / Trans-Activators; 0 / alpha Catenin; 0 / beta Catenin; 0 / gamma Catenin
  •  go-up   go-down


67. Ecke TH, Schlechte HH, Schulze G, Lenk SV, Loening SA: Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation. Anticancer Res; 2005 Jan-Feb;25(1B):635-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
  • HER-2/neu protein is a transmembrane tyrosine kinase cell surface growth factor receptor that is expressed on normal epithelial and some cancer cells.
  • Mutations of the tumour suppressor gene P53 (TP53) are frequently correlated with tumour development and progression.
  • We compared TPA, HER-2/neu and uPAR, and TP53 mutation in tumour-free and bladder cancer patients.
  • MATERIALS AND METHODS: Clinical samples were used from 60 patients with tumours of the urinary bladder and from 9 patients with benign urological diseases.
  • TP53 mutation frequently occurs in higher stages of bladder tumours.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Genes, p53 / genetics. Mutation. Receptor, ErbB-2 / biosynthesis. Receptors, Cell Surface / biosynthesis. Tissue Polypeptide Antigen / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis. Urinary Bladder Neoplasms / metabolism

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816639.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / PLAUR protein, human; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; 0 / Tissue Polypeptide Antigen; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


68. Halldorsson A, Dissanaike S, Kaye KS: Alveolar adenoma of the lung: a clinicopathological description of a case of this very unusual tumour. J Clin Pathol; 2005 Nov;58(11):1211-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar adenoma of the lung: a clinicopathological description of a case of this very unusual tumour.
  • Alveolar adenomas are extremely rare, and are probably benign lung tumours of unknown histogenesis.
  • Although a positron emission tomography scan seemed to document the benign nature of the lesion, a thoracoscopic wedge resection was performed to alleviate the symptoms and verify the diagnosis.
  • The cystic cell linings were mostly indistinct, although areas of cuboidal epithelial cells were seen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Surg Pathol. 2004 Apr;12(2):155-9 [15173924.001]
  • [Cites] Pathologe. 1990 Jan;11(1):48-54 [2179944.001]
  • [Cites] Pathologe. 1996 Mar;17(2):150-3 [8650145.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Jul 1;89(1):34-7 [8689607.001]
  • [Cites] Virchows Arch. 1996 Oct;429(2-3):101-8 [8917711.001]
  • [Cites] Virchows Arch. 1997 Feb;430(2):181-4 [9083522.001]
  • [Cites] Pol J Pathol. 2003;54(2):147-52 [14575424.001]
  • [Cites] Cesk Patol. 1997 May;33(2):49-52 [9340215.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):158-67 [10029443.001]
  • [Cites] Hum Pathol. 1986 Oct;17(10):1066-71 [3759064.001]
  • [Cites] Ann Pathol. 1999 Sep;19(4):325-8 [10544770.001]
  • [Cites] J Thorac Imaging. 2002 Apr;17(2):163-6 [11956369.001]
  • [Cites] Rontgenpraxis. 1997 Feb;50(2):29-30 [9173555.001]
  • (PMID = 16254114.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770767
  •  go-up   go-down


69. Wang XY, Xu SJ, Li XG: Post-operative implantation metastasis of craniopharyngioma: a case report. J Int Med Res; 2010 Sep-Oct;38(5):1876-82
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Craniopharyngiomas are histologically benign epithelial tumours arising from squamous epithelial remnants of Rathke's pouch, which have a tendency to invade surrounding structures and recur after apparently complete resection.
  • They represent the most frequent non-glial tumour in children, accounting for approximately 5% of paediatric brain neoplasms.
  • Total resection of a craniopharyngioma may be difficult, and recurrence has been reported in 25-70% of patients.
  • [MeSH-major] Craniopharyngioma / secondary. Neoplasm Recurrence, Local / pathology. Pituitary Neoplasms / pathology

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21309505.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


70. Gakiopoulou H, Korkolopoulou P, Levidou G, Thymara I, Saetta A, Piperi C, Givalos N, Vassilopoulos I, Ventouri K, Tsenga A, Bamias A, Dimopoulos MA, Agapitos E, Patsouris E: Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications. Br J Cancer; 2007 Oct 22;97(8):1124-34
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications.
  • Minichromosome maintenance proteins (MCM) have recently emerged as novel proliferation markers with prognostic implications in several tumour types.
  • This is the first study investigating MCM-2 and MCM-5 immunohistochemical expression in a series of ovarian adenocarcinomas and low malignant potential (LMP) tumours aiming to determine possible associations with clinicopathological parameters, the conventional proliferation index Ki-67, cell cycle regulators (p53, p27(Kip1), p21(WAF1) and pRb) and patients' outcome.
  • Immunohistochemistry was applied in a series of 43 cases of ovarian LMP tumours and 85 cases of adenocarcinomas.
  • The median MCM-2 and MCM-5 labelling indices (LIs) were significantly higher in adenocarcinomas compared to LMP tumours (P<0.0001 for both associations).
  • In adenocarcinomas, the levels of MCM-2 and MCM-5 increased significantly with advancing tumour stage (P=0.0052 and P=0.0180, respectively), whereas both MCM-2 and MCM-5 increased significantly with increasing tumour grade (P=0.0002 and P=0.0006, respectively) and the presence of bulky residual disease (P<0.0001 in both relationships).
  • [MeSH-major] Cell Cycle Proteins / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Nuclear Proteins / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Minichromosome Maintenance Complex Component 2. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Jun;31(6):698-704 [10872663.001]
  • [Cites] Hum Pathol. 2005 Aug;36(8):899-907 [16112007.001]
  • [Cites] Curr Opin Genet Dev. 2001 Feb;11(1):64-70 [11163153.001]
  • [Cites] J Cell Sci. 2001 Apr;114(Pt 8):1447-54 [11282021.001]
  • [Cites] Int J Gynecol Cancer. 2001 May-Jun;11(3):187-93 [11437923.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):2027-41 [11493639.001]
  • [Cites] Neuropathol Appl Neurobiol. 2001 Aug;27(4):305-13 [11532161.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2712-8 [11555583.001]
  • [Cites] Eur J Cancer. 2000 Dec;36(18):2317-28 [11094305.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):2984-97 [11595686.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4259-66 [11709570.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Pathobiology. 2001;69(3):150-8 [11872961.001]
  • [Cites] Br J Neurosurg. 2002 Feb;16(1):10-5 [11928726.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1075-81 [11948116.001]
  • [Cites] Gynecol Oncol. 2002 Jun;85(3):404-14 [12051866.001]
  • [Cites] Cancer J. 2002 May-Jun;8 Suppl 1:S22-30 [12075699.001]
  • [Cites] Int J Mol Med. 2002 Aug;10(2):161-8 [12119552.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):389-404 [12518363.001]
  • [Cites] Eur Urol. 2003 Feb;43(2):138-45 [12565771.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):185-97 [12620412.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):369-78 [12648589.001]
  • [Cites] Histol Histopathol. 2003 Jul;18(3):761-70 [12792888.001]
  • [Cites] J Oral Pathol Med. 2003 Sep;32(8):468-74 [12901728.001]
  • [Cites] J Surg Oncol. 2003 Sep;84(1):24-30 [12949987.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [12917485.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4306-13 [14645419.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1583-90 [15083189.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):2962-8 [15126326.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3103-11 [15126347.001]
  • [Cites] J Mol Biol. 2004 Jul 23;340(5):1197-206 [15236977.001]
  • [Cites] Pathobiology. 2004;71(4):193-200 [15263808.001]
  • [Cites] Control Clin Trials. 1981 Jun;2(2):93-113 [7273794.001]
  • [Cites] Eur J Biochem. 1986 Sep 15;159(3):529-34 [2428616.001]
  • [Cites] Biometrics. 1986 Sep;42(3):507-19 [3567285.001]
  • [Cites] J Cell Physiol. 2000 Mar;182(3):371-80 [10653604.001]
  • [Cites] Anticancer Res. 1999 Nov-Dec;19(6B):4935-45 [10697493.001]
  • [Cites] Exp Cell Res. 2005 Sep 10;309(1):56-67 [16005865.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):939-45 [16189522.001]
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1295-300 [16278669.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Mar;132(3):163-70 [16328436.001]
  • [Cites] Anticancer Res. 2006 Mar-Apr;26(2A):1071-5 [16619508.001]
  • [Cites] Lab Invest. 2001 Aug;81(8):1163-5 [11502867.001]
  • [Cites] Gene. 2000 Mar 7;245(1):13-20 [10713440.001]
  • [Cites] Arch Pathol Lab Med. 1987 Sep;111(9):794-5 [3632298.001]
  • [Cites] Nature. 1988 Apr 7;332(6164):546-8 [3357511.001]
  • [Cites] Biol Cell. 1991;72(1-2):47-50 [1756311.001]
  • [Cites] J Cell Sci. 1994 Jan;107 ( Pt 1):253-65 [8175912.001]
  • [Cites] EMBO J. 1997 Jun 2;16(11):3312-9 [9214646.001]
  • [Cites] EMBO J. 1997 Jun 2;16(11):3320-31 [9214647.001]
  • [Cites] Eur J Biochem. 1997 Jul 1;247(1):136-41 [9249019.001]
  • [Cites] Lab Invest. 1998 Jan;78(1):73-8 [9461123.001]
  • [Cites] Exp Cell Res. 1998 May 25;241(1):260-4 [9633535.001]
  • [Cites] Leukemia. 1998 Aug;12(8):1256-65 [9697881.001]
  • [Cites] J Biol Chem. 1998 Sep 18;273(38):24543-9 [9733749.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1870-8 [10206307.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2121-32 [10473096.001]
  • [Cites] J Cell Sci. 2004 Nov 15;117(Pt 24):5875-86 [15522891.001]
  • [Cites] J Pathol. 2005 Jan;205(2):123-9 [15643673.001]
  • [Cites] Annu Rev Biochem. 1999;68:649-86 [10872463.001]
  • (PMID = 17940502.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / MCM5 protein, human; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  • [Other-IDs] NLM/ PMC2360432
  •  go-up   go-down


71. Zhou J, Ye F, Chen H, Lv W, Gan N: The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines. J Int Med Res; 2007 May-Jun;35(3):290-300
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines.
  • Expression of IL-10 in ovarian carcinoma, benign ovarian tumour, normal control tissues and ovarian carcinoma cell lines was detected by immunohistochemistry and Western blot analysis.
  • IL-10 concentrations in sera and ascites from patients with ovarian carcinoma, in sera from patients with benign ovarian tumour and normal controls, and in supernatants of ovarian carcinoma cell line cultures were measured by enzyme-linked immunosorbent assay.
  • The tissue level of IL-10 in ovarian carcinoma was significantly higher than in benign ovarian tumour and normal controls.
  • In patients with ovarian carcinoma the IL-10 level in ascitic fluid was significantly higher than in sera, and the serum IL-10 level in ovarian carcinoma was significantly higher than in benign ovarian tumour and normal controls.
  • [MeSH-major] Carcinoma / metabolism. Interleukin-10 / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Ascitic Fluid / metabolism. Blotting, Western. Cell Line, Tumor. Female. Humans. Middle Aged. Reference Values

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593856.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 130068-27-8 / Interleukin-10
  •  go-up   go-down


72. Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, Findlay J, Ackland L, Ahmed N: Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer; 2009 Jan 13;100(1):134-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas.
  • Epidermal growth factor receptor (EGFR) is overexpressed in ovarian carcinomas, with direct or indirect activation of EGFR able to trigger tumour growth.
  • We demonstrate significant activation of both signal transducer and activator of transcription (STAT)3 and its upstream activator Janus kinase (JAK)2, in high-grade ovarian carcinomas compared with normal ovaries and benign tumours.
  • The association between STAT3 activation and migratory phenotype of ovarian cancer cells was investigated by EGF-induced epithelial-mesenchymal transition (EMT) in OVCA 433 and SKOV3 ovarian cancer cell lines.
  • Specific inhibition of STAT3 activation by JAK2-specific inhibitor AG490 blocked STAT3 phosphorylation, cell motility, induction of N-cadherin and vimentin expression and IL6 production.
  • Such activation of STAT3 suggests a rationale for a combination of anti-STAT3 and EGFR/IL-6R therapy to suppress the peritoneal spread of ovarian cancer.
  • [MeSH-major] Epithelial Cells / cytology. Janus Kinase 2 / physiology. Mesoderm / cytology. Ovarian Neoplasms / pathology. Receptor Cross-Talk / physiology. Receptor, Epidermal Growth Factor / physiology. Receptors, Interleukin-6 / physiology. STAT3 Transcription Factor / physiology
  • [MeSH-minor] Antigens, CD / analysis. Cadherins / analysis. Cell Line, Tumor. Epidermal Growth Factor / pharmacology. Female. Humans. Interleukin-6 / biosynthesis. Leukemia Inhibitory Factor / biosynthesis. Vimentin / analysis. beta Catenin / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6351-9 [17616694.001]
  • [Cites] Cells Tissues Organs. 2007;185(1-3):85-94 [17587812.001]
  • [Cites] BMC Cancer. 2007;7:111 [17598902.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9066-76 [17909010.001]
  • [Cites] J Cell Physiol. 2007 Dec;213(3):581-8 [17708542.001]
  • [Cites] Neoplasia. 2007 Oct;9(10):820-9 [17971902.001]
  • [Cites] Cell. 2007 Nov 30;131(5):1018 [18045542.001]
  • [Cites] J Clin Invest. 2007 Dec;117(12):3846-56 [18060032.001]
  • [Cites] Int J Biochem Cell Biol. 2009 May;41(5):1034-45 [18930836.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jan;19(1):7-15 [10638449.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):383-91 [11196191.001]
  • [Cites] Oncogene. 2001 May 3;20(20):2499-513 [11420660.001]
  • [Cites] Cell. 2001 Dec 28;107(7):831-41 [11779460.001]
  • [Cites] Carcinogenesis. 2002 Feb;23(2):237-44 [11872628.001]
  • [Cites] Dev Cell. 2002 Mar;2(3):363-75 [11879641.001]
  • [Cites] Cytokine. 2002 Mar 21;17(6):324-34 [12061840.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Sep;3(9):651-62 [12209125.001]
  • [Cites] J Histochem Cytochem. 2002 Oct;50(10):1371-80 [12364570.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Jan;4(1):13-24 [12511865.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2948-56 [12782602.001]
  • [Cites] J Pathol. 2003 Oct;201(2):229-37 [14517840.001]
  • [Cites] Hum Reprod. 2004 Jan;19(1):21-9 [14688152.001]
  • [Cites] J Am Soc Nephrol. 2004 Jan;15(1):21-32 [14694154.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2382-9 [15059889.001]
  • [Cites] IUBMB Life. 2004 Feb;56(2):83-8 [15085931.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3550-8 [15150111.001]
  • [Cites] Mol Vis. 2004 Jul 15;10:462-7 [15273655.001]
  • [Cites] Mol Reprod Dev. 2004 Sep;69(1):1-10 [15278897.001]
  • [Cites] Am J Kidney Dis. 1995 Oct;26(4):678-90 [7573028.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3801-4 [9108058.001]
  • [Cites] EMBO J. 1999 Sep 1;18(17):4657-68 [10469645.001]
  • [Cites] Exp Cell Res. 2004 Dec 10;301(2):128-38 [15530849.001]
  • [Cites] Trends Endocrinol Metab. 2004 Dec;15(10):461-3 [15541644.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1475-85 [15798771.001]
  • [Cites] Oncology (Williston Park). 2005 Apr;19(4):553-9; discussion 560-2, 567 [15934521.001]
  • [Cites] Neoplasia. 2005 Apr;7(4):426-31 [15967120.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8637-43 [16361548.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):879-88 [16152587.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Jun;290(6):C1532-42 [16394028.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2730-40 [17063503.001]
  • [Cites] Breast Cancer Res. 2007;9(1):R19 [17311675.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2426-34 [17294443.001]
  • [Cites] J Appl Physiol (1985). 2007 Apr;102(4):1483-9 [17204573.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1153-62 [17272306.001]
  • [Cites] Cells Tissues Organs. 2007;185(1-3):61-5 [17587809.001]
  • [Cites] J Cell Sci. 2007 Sep 1;120(Pt 17):3138-46 [17698922.001]
  • (PMID = 19088723.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CDH2 protein, human; 0 / Cadherins; 0 / Interleukin-6; 0 / LIF protein, human; 0 / Leukemia Inhibitory Factor; 0 / Receptors, Interleukin-6; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / Vimentin; 0 / beta Catenin; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Other-IDs] NLM/ PMC2634691
  •  go-up   go-down


73. Ethunandan M, Davies B, Pratt CA, Puxeddu R, Brennan PA: Primary epithelial submandibular salivary gland tumours--review of management in a district general hospital setting. Oral Oncol; 2009 Feb;45(2):173-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary epithelial submandibular salivary gland tumours--review of management in a district general hospital setting.
  • Primary epithelial submandibular gland (SMG) tumours are uncommon, accounting for 8-12% of all salivary gland neoplasms, and most studies come from large specialised centres.
  • There is little published about the relative frequency and outcome of SMG tumours treated in general hospitals.
  • Seventeen benign (68%) and eight malignant (32%) tumours were included.
  • Pleomorphic adenoma accounted for all 17 benign tumours and adenoid cystic carcinoma was the commonest malignant tumour.
  • Fine needle aspiration cytology (FNAC) accurately identified 78% of the benign tumours but none of the malignant tumours.
  • Pre-operative imaging was also unable to distinguish malignant from benign tumours.
  • Incomplete excision was reported in 20% of cases and was more common for malignant tumours.
  • It may be difficult to distinguish benign from malignant SMG tumours on clinical examination and pre-operative investigations.
  • Any suspected submandibular tumour should be considered for early treatment even when FNAC is suggestive of a benign tumour.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / diagnosis. Submandibular Gland Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18676173.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


74. Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K: Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer; 2006;5:62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression.
  • BACKGROUND: The involvement of the cyclooxygenases (COX), in particular COX-2, is well documented for many tumours, e.g. colon, breast and prostate cancer, by both experimental and clinical studies.
  • One of the end products of PG-synthesis, PGE2, regulates several key-processes, which are characteristic for tumour growth, e.g. angiogenesis, proliferation and apoptosisis.
  • The present study investigated the pathway for PGE2-synthesis and signalling in ovarian tumourigenesis by analysing specimen from normal ovaries (n = 18), benign (B) (n = 8), borderline type (BL) (n = 6) and malignant tumours (AC) (n = 22).
  • RESULTS: The results are in line with earlier studies demonstrating an increase of COX-2 in AC compared to the normal ovary, B and BL tumours.
  • The increase of COX-2 was also correlated to stage (FIGO classification) with significant elevations in stages II and III.
  • IHC revealed staining of the tumour cells, but also increase of COX-1, COX-2, mPGES-1 and EP1-2 in the stromal compartment of AC (grades: moderately-, poorly- and undifferentiated).
  • This observation suggests interactions between tumour cells and stromal cells (fibroblasts, immune cells), e.g. paracrine signalling mediated by growth factors, cytokines and possibly PGs.
  • CONCLUSION: The increases of COX-1, COX-2, mPGES-1 and EP1-2 in epithelial ovarian cancer, supports the hypothesis that PGE2-synthesis and signalling are of importance for malignant transformation and progression.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cyclooxygenase 1 / metabolism. Cyclooxygenase 2 / metabolism. Densitometry. Disease Progression. Epithelial Cells / pathology. Female. Humans. Immunoblotting. Immunohistochemistry. Intramolecular Oxidoreductases / metabolism. Neoplasm Staging. Ovary / metabolism. Receptors, Prostaglandin E / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Soc Gynecol Investig. 2002 May-Jun;9(3):168-73 [12009392.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2002;21(2):149-53 [12086401.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1205-11 [12181243.001]
  • [Cites] J Reprod Immunol. 2002 Oct-Nov;57(1-2):47-60 [12385833.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):906-11 [12615701.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1423-9 [14508829.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1298-304 [14520463.001]
  • [Cites] Prog Lipid Res. 2004 Jan;43(1):3-35 [14636669.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8653-61 [14647459.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2607-23 [14669280.001]
  • [Cites] Oncol Rep. 2004 Feb;11(2):309-13 [14719060.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):538-45 [14760075.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):622-7 [14766256.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4670-9 [15269139.001]
  • [Cites] Acta Obstet Gynecol Scand. 2004 Sep;83(9):783-95 [15315588.001]
  • [Cites] Reproduction. 2004 Nov;128(5):607-14 [15509706.001]
  • [Cites] Lancet. 1971 Jul 17;2(7716):163 [4104488.001]
  • [Cites] Gynecol Oncol. 1983 Dec;16(3):340-5 [6360817.001]
  • [Cites] Gynecol Obstet Invest. 1984;18(5):225-9 [6396175.001]
  • [Cites] Prostaglandins. 1985 May;29(5):665-72 [3859890.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):275-80 [9221804.001]
  • [Cites] J Histochem Cytochem. 1998 Jan;46(1):77-84 [9405496.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1240-8 [10098766.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10501-6 [10468638.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67 [10469746.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1927-33 [15870720.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Aug;73(2):103-11 [15963707.001]
  • [Cites] Oncogene. 2005 Dec 1;24(54):7991-8002 [16044148.001]
  • [Cites] Nucleic Acids Res. 2006;34(1):217-31 [16397300.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1884-91 [16287068.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):130-40 [16491072.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2527-31 [16510568.001]
  • [Cites] Curr Pharm Des. 2006;12(8):943-54 [16533161.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Am J Obstet Gynecol. 2005 Mar;192(3):819-25 [15746677.001]
  • [Cites] Oncol Rep. 2005 Apr;13(4):559-83 [15756426.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2234-42 [15781636.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3735-44 [15867369.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3250-6 [15867220.001]
  • [Cites] J Reprod Fertil. 2000 Mar;118(2):375-85 [10864803.001]
  • [Cites] Epidemiology. 2000 Mar;11(2):111-7 [11021606.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):849-53 [11238034.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:661-90 [11264472.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2328-34 [11280806.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Int J Mol Med. 2001 Jul;8(1):31-6 [11408945.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2496-504 [11489832.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1048-51 [11533709.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7305-9 [11585770.001]
  • [Cites] Int J Mol Med. 2001 Dec;8(6):603-6 [11712072.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):202-9 [11801560.001]
  • [Cites] Annu Rev Physiol. 2002;64:69-92 [11826264.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):893-903 [11891188.001]
  • (PMID = 17107625.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Prostaglandin E; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.3 / prostaglandin-E synthase; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC1657027
  •  go-up   go-down


75. Tse GM, Wong FC, Tsang AK, Lee CS, Lui PC, Lo AW, Law BK, Scolyer RA, Karim RZ, Putti TC: Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour. J Clin Pathol; 2005 Jun;58(6):600-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour.
  • In mammary fibroepithelial lesions, NOS expression in stromal cells has been reported to be lower in fibroadenomas than in phyllodes tumours.
  • AIMS: To investigate NOS expression in phyllodes tumours of varying degrees of malignancy.
  • METHODS: One hundred and sixty seven mammary phyllodes tumours (97 benign, 47 borderline malignant, and 23 frankly malignant) were evaluated for e-NOS and i-NOS expression by immunohistochemistry.
  • RESULTS: Stromal expression of e-NOS was absent, weak, moderate, and strong in 43%, 31%, 13%, and 13% of benign tumours; 17%, 26%, 13%, and 44% of borderline malignant tumours; and 17%, 35%, 13%, and 35% of frankly malignant tumours, respectively.
  • Stromal expression of i-NOS was 77%, 18%, 4%, and 1% in benign tumours; 42%, 28%, 19%, and 11% in borderline malignant tumours; and 43%, 13%, 26%, and 18% in frankly malignant tumours, respectively.
  • Stromal expression of both i-NOS and e-NOS was significantly different between the benign and malignant (borderline and frank) groups of phyllodes tumours (p < 0.0001).
  • The expression of NOS in the epithelial cells was strong, and showed no differences between the different groups of tumours.
  • CONCLUSIONS: Higher stromal expression of NOS in phyllodes tumours is associated with malignancy, suggesting a possible role in malignant progression, particularly metastasising potential.
  • [MeSH-major] Breast Neoplasms / enzymology. Nitric Oxide Synthase / metabolism. Phyllodes Tumor / enzymology
  • [MeSH-minor] Adolescent. Adult. Aged. Disease Progression. Epithelial Cells / enzymology. Female. Humans. Middle Aged. Neovascularization, Pathologic. Nitric Oxide Synthase Type II. Nitric Oxide Synthase Type III. Stromal Cells / enzymology. Vascular Endothelial Growth Factor A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lab Invest. 1999 Oct;79(10):1215-25 [10532585.001]
  • [Cites] Cancer Lett. 1999 Sep 20;144(1):65-74 [10503879.001]
  • [Cites] Tumour Biol. 2000 Mar-Apr;21(2):90-7 [10686538.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2408-16 [10873093.001]
  • [Cites] Int J Oncol. 2000 Oct;17(4):667-71 [10995876.001]
  • [Cites] Histochem Cell Biol. 2002 Jan;117(1):13-9 [11819093.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):734-40 [12118111.001]
  • [Cites] Cancer. 2002 Sep 15;95(6):1191-8 [12216084.001]
  • [Cites] Eur J Surg Oncol. 2003 Sep;29(7):619-23 [12943630.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):1007-13 [14559983.001]
  • [Cites] Hum Pathol. 2004 Sep;35(9):1053-7 [15343505.001]
  • [Cites] Radiology. 1983 Feb;146(2):481-6 [6294737.001]
  • [Cites] J Exp Med. 1989 May 1;169(5):1543-55 [2497225.001]
  • [Cites] Surg Gynecol Obstet. 1990 Mar;170(3):193-6 [2154867.001]
  • [Cites] J Surg Oncol. 1990 Sep;45(1):46-51 [2166186.001]
  • [Cites] Br J Pharmacol. 1992 Dec;107(4):1092-5 [1281718.001]
  • [Cites] Am J Surg. 1993 Mar;165(3):376-9 [8383473.001]
  • [Cites] J Immunol. 1993 Apr 15;150(8 Pt 1):3478-86 [8385686.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1352-4 [7509718.001]
  • [Cites] Biochem J. 1994 Mar 1;298 ( Pt 2):249-58 [7510950.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2462-7 [8162595.001]
  • [Cites] Lancet. 1994 May 14;343(8907):1199-206 [7909873.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):727-30 [7531613.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4392-6 [7538668.001]
  • [Cites] Br J Cancer. 1995 Jul;72(1):41-4 [7541238.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Nov;113(5):541-9 [7478643.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Jul 5;224(1):153-8 [8694803.001]
  • [Cites] Br J Cancer. 1996 Nov;74(9):1423-6 [8912539.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):645-9 [9237172.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3365-9 [9269997.001]
  • [Cites] Carcinogenesis. 1997 Sep;18(9):1841-5 [9328184.001]
  • [Cites] Free Radic Biol Med. 1998 Jan 15;24(2):341-8 [9433910.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):334-41 [9443414.001]
  • [Cites] Cancer. 1998 May 15;82(10):1897-903 [9587122.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):2929-34 [9679948.001]
  • [Cites] Br J Cancer. 1998 Jul;78(2):233-9 [9683299.001]
  • [Cites] Lab Invest. 1998 Aug;78(8):949-55 [9714182.001]
  • [Cites] Jpn J Cancer Res. 1998 Jul;89(7):696-702 [9738975.001]
  • [Cites] J Urol. 1999 Feb;161(2):630-4 [9915473.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):1093-7 [10353743.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jul;56(2):145-51 [10573107.001]
  • (PMID = 15917410.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / NOS3 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.13.39 / Nitric Oxide Synthase Type III
  • [Other-IDs] NLM/ PMC1770683
  •  go-up   go-down


76. Gromov P, Gromova I, Bunkenborg J, Cabezon T, Moreira JM, Timmermans-Wielenga V, Roepstorff P, Rank F, Celis JE: Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast. Mol Oncol; 2010 Feb;4(1):65-89
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast.
  • Here we describe a detailed analysis using gel-based proteomics in combination with mass spectrometry and immunohistochemistry (IHC) of the tumour interstitial fluids (TIF) and normal interstitial fluids (NIF) collected from 69 prospective breast cancer patients.
  • The goal of this study was to identify abundant cancer up-regulated proteins that are externalised by cells in the tumour microenvironment of most if not all these lesions.
  • To this end, we chose to use samples derived from a single tumour/benign tissue pair (patient 46, triple negative tumour), for which we had well-matched samples in terms of epithelial cell numbers, to generate the initial dataset.
  • [MeSH-major] Biomarkers / metabolism. Biomarkers, Tumor / metabolism. Breast Neoplasms / diagnosis. Neoplasm Staging / classification


77. den Bakker MA, Oosterhuis JW: Tumours and tumour-like conditions of the thymus other than thymoma; a practical approach. Histopathology; 2009 Jan;54(1):69-89
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumours and tumour-like conditions of the thymus other than thymoma; a practical approach.
  • Despite the fact that the pathology of the anterior mediastinum is predominantly centred on the thymus and it thus might be expected that the range of possible diagnoses is limited, the list of disease entities is in fact extensive, encompassing hyperplastic conditions and both benign and malignant neoplasms.
  • In addition to primary thymic epithelial tumours, a number of less common diseases typical for this location may be encountered, including extragonadal germ cell tumours, lymphomas, soft tissue tumours and a number of conditions which may simulate a tumour, such as cysts and inflammatory conditions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19054157.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 176
  •  go-up   go-down


78. Bernard-Pierrot I, Brams A, Dunois-Lardé C, Caillault A, Diez de Medina SG, Cappellen D, Graff G, Thiery JP, Chopin D, Ricol D, Radvanyi F: Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis; 2006 Apr;27(4):740-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surprisingly, identical somatic activating mutations have been found at the somatic level in tumours: at high frequency in benign epithelial tumours (seborrheic keratosis, urothelial papilloma) and in low-grade, low-stage urothelial carcinomas, and at a lower frequency in other types of urothelial carcinoma, in cervix carcinoma, and in haematological cancer, multiple myeloma.
  • FGFR3b is the main form in epithelial cells and derived tumours, whereas FGFR3c is the main form in mesenchyme-derived cells and multiple myeloma.
  • Although mutated FGFR3b is mostly found in benign epithelial tumours or carcinomas of low malignant potential, we present evidence here that mutated FGFR3b is oncogenic.
  • All bladder tumours presenting FGFR3 mutations expressed this receptor more strongly than normal urothelium or non-mutated tumours.
  • NIH-3T3 cells transfected with a mutated form of FGFR3b--FGFR3b-S249C, the most common mutation in bladder tumours--presented a spindle-cell morphology, grew in soft agar and gave rise to tumours when xenografted into nude mice.
  • We showed using siRNA and SU5402, an FGFR inhibitor, that the tumour properties of MGH-U3 depended on mutated receptor activity.
  • [MeSH-minor] Animals. DNA Mutational Analysis. Epithelial Cells. Female. Fibroblasts. Humans. Mice. Mice, Nude. Protein Isoforms. Pyrroles / pharmacology. RNA, Small Interfering. Receptor, Fibroblast Growth Factor, Type 3. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16338952.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / Pyrroles; 0 / RNA, Small Interfering; 0 / SU 5402; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3
  •  go-up   go-down


79. Shukla CJ, Pennington CJ, Riddick AC, Sethia KK, Ball RY, Edwards DR: Laser-capture microdissection in prostate cancer research: establishment and validation of a powerful tool for the assessment of tumour-stroma interactions. BJU Int; 2008 Mar;101(6):765-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laser-capture microdissection in prostate cancer research: establishment and validation of a powerful tool for the assessment of tumour-stroma interactions.
  • As LCM allows the separation of benign and malignant epithelial structures and stromal elements, it not only allows identification of the source of the biomarker, but might also accentuate gene or protein expression changes by reducing contamination by other cellular elements.
  • RESULTS: Prostate-specific antigen (PSA) and cytokeratin 8, were expressed solely by epithelial cells, whereas hepatocyte growth factor (HGF) and tissue inhibitor of metalloproteinases-3 (TIMP3) were expressed only by stromal cells, and the levels of transcripts of these genes were unaltered between benign and malignant tissues.
  • CONCLUSIONS: These data suggest that PSA, cytokeratin 8, HGF and TIMP3 are reliable gene markers of purity of epithelial and stromal compartments for LCM of prostate tumours.
  • [MeSH-major] Lasers. Microdissection / methods. Prostate / pathology. Prostatic Neoplasms / pathology. RNA, Neoplasm / analysis
  • [MeSH-minor] Epithelial Cells / pathology. Gene Expression. Hepatocyte Growth Factor / metabolism. Humans. In Situ Hybridization. Keratin-8 / metabolism. Male. Prostate-Specific Antigen / metabolism. Stromal Cells / pathology. Tissue Inhibitor of Metalloproteinase-3 / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18190638.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ G0100250
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-8; 0 / RNA, Neoplasm; 0 / Tissue Inhibitor of Metalloproteinase-3; 67256-21-7 / Hepatocyte Growth Factor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


80. Zhang J, Jianmin, Wang N, Shi J, Ge X: A case of primary oncocytic adenocarcinoma of the lacrimal sac. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lacrimal sac tumours are rare entities.
  • Neoplasms of the lacrimal system may conveniently be grouped into epithelial and non-epithelial types: papillomas are the most common benign epithelial tumours, while oncocytic adenocarcinomas are extremely rare.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Orbit. 2005 Dec;24(4):291-3 [16354642.001]
  • [Cites] Ophthalmology. 1980 Jun;87(6):476-90 [7413136.001]
  • [Cites] Ear Nose Throat J. 1995 Oct;74(10):717-20 [8529551.001]
  • [Cites] Ophthalmic Surg. 1995 Jul-Aug;26(4):377-9 [8532297.001]
  • [Cites] Arch Ophthalmol. 1978 Feb;96(2):303-4 [629677.001]
  • (PMID = 21747898.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029480
  •  go-up   go-down


81. Sharma V, Koirala K: Lateral rhinotomy vs mid-facial degloving for T3 inverted papilloma of nose and paranasal sinus. Nepal Med Coll J; 2009 Jun;11(2):115-7
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inverted papillomas are rare, benign epithelial tumours of the nasal cavity and paranasal sinuses.
  • All patients initially underwent nasal biopsy for confirmation of the diagnosis and pre-operative C.T. scan for tumour staging.
  • [MeSH-minor] Aged. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19968152.001).
  • [Journal-full-title] Nepal Medical College journal : NMCJ
  • [ISO-abbreviation] Nepal Med Coll J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


82. Veveris-Lowe TL, Lawrence MG, Collard RL, Bui L, Herington AC, Nicol DL, Clements JA: Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer; 2005 Sep;12(3):631-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.
  • In this study, we now show that the comparative expression of hK4 protein in prostate cancer tissues, compared with benign glands, is greater than that of PSA and kallikrein 2 (KLK2/hK2), suggesting that hK4 may play an important functional role in prostate cancer progression in addition to its biomarker potential.
  • We hypothesised that this increase in motility displayed by the hK4 and PSA-expressing PC-3 cells may be related to the observed change in structure in these cells from a typical rounded epithelial-like cell to a spindle-shaped, more mesenchymal-like cell, with compromised adhesion to the culture surface.
  • Thus, the expression of E-cadherin and vimentin, both associated with an epithelial-mesenchymal transition (EMT), was investigated.
  • The loss of E-cadherin and associated increase in vimentin are indicative of EMT and provides compelling evidence that hK4, in particular, and PSA have a functional role in the progression of prostate cancer through their promotion of tumour cell migration.
  • [MeSH-minor] Cell Division. Cell Line, Tumor. Cell Movement. Epithelial Cells / pathology. Humans. Male. Mesoderm / pathology. Neoplasm Invasiveness


83. Tse GM, Chaiwun B, Lau KM, Scolyer R, Lee CS, Karim RZ, Putti TC, Law BK, Lui PC, Tan PH: Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours. J Clin Pathol; 2007 Sep;60(9):1051-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours.
  • BACKGROUND AND AIMS: Endothelin-1 expression is increased in infiltrating duct carcinoma and is associated with larger tumour size, higher histological grade and lymphovascular permeation.
  • This has not been evaluated in phyllodes tumours, which are uncommon fibroepithelial lesions with potential for local recurrences or distant metastasis.
  • While the grading of phyllodes tumours depends on a combination of histological parameters, prediction of their behaviour remains difficult.
  • METHOD: A large series of 461 phyllodes tumours (291 benign, 115 borderline malignant and 55 frankly malignant) were evaluated for endothelin-1 expression in both the epithelial cells and stromal cells by immunohistochemistry; results were correlated with the tumour grade.
  • RESULTS: For benign phyllodes tumours, the epithelial staining of endothelin was negative, weak, moderate and strong in 6%, 26%, 15% and 53% of cases respectively; results were 4%, 18%, 19% and 59% respectively for borderline and 6%, 18%, 6% and 70% respectively for frankly malignant tumours.
  • For the stromal staining, the negative, weak, moderate and strong staining was 32%, 19%, 18% and 31% respectively for benign phyllodes, 24%, 13%, 10% and 53% respectively for borderline and 8%, 16%, 17% and 59% respectively for frankly malignant tumours.
  • There was correlation between epithelial and stromal staining, and the stromal staining correlated with histological features of stromal cellularity, stromal cell nuclear pleomorphism, margin status and stromal overgrowth.
  • CONCLUSION: These observations suggest a close relationship between the epithelial and stromal elements in phyllodes tumours; endothelin may play a significant role in the malignant progression of phyllodes tumours.
  • [MeSH-major] Breast Neoplasms / metabolism. Endothelin-1 / metabolism. Neoplasm Proteins / metabolism. Phyllodes Tumor / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Nucleus / pathology. Epithelial Cells / metabolism. Female. Humans. Middle Aged. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1995 Sep;27(3):205-18 [8522284.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):910-6 [8608483.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27850-5 [12023962.001]
  • [Cites] Nature. 1988 Mar 31;332(6163):411-5 [2451132.001]
  • [Cites] FEBS Lett. 1988 Apr 25;231(2):440-4 [3282927.001]
  • [Cites] J Biol Chem. 1989 May 15;264(14):7856-61 [2542249.001]
  • [Cites] Surg Gynecol Obstet. 1990 Mar;170(3):193-6 [2154867.001]
  • [Cites] J Surg Oncol. 1990 Sep;45(1):46-51 [2166186.001]
  • [Cites] J Exp Med. 1990 Dec 1;172(6):1741-8 [1701822.001]
  • [Cites] Cancer. 1992 Jan 1;69(1):141-7 [1309302.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):720-7 [9973223.001]
  • [Cites] Pathol Res Pract. 1998;194(2):97-104 [9584322.001]
  • [Cites] Cancer Res. 1992 Jul 15;52(14):4046-9 [1319837.001]
  • [Cites] Eur J Pharmacol. 1999 Jun 30;375(1-3):133-8 [10443571.001]
  • [Cites] Histopathology. 1999 Aug;35(2):162-9 [10460662.001]
  • [Cites] Pathol Int. 1999 Sep;49(9):807-10 [10504552.001]
  • [Cites] Am J Clin Pathol. 2005 Apr;123(4):529-40 [15743740.001]
  • [Cites] Cancer Lett. 2005 May 26;222(2):129-38 [15863261.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1720-8 [15841074.001]
  • [Cites] Surg Oncol. 1995;4(6):309-15 [8809953.001]
  • [Cites] Histopathology. 2000 Feb;36(2):161-7 [10672062.001]
  • [Cites] Genomics. 2000 Feb 15;64(1):51-61 [10708518.001]
  • [Cites] Am J Respir Cell Mol Biol. 2000 Apr;22(4):422-31 [10745023.001]
  • [Cites] BJU Int. 2000 Apr;85 Suppl 2:45-8 [10781185.001]
  • [Cites] Eur J Immunol. 2002 Sep;32(9):2393-400 [12207323.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Jan;51(1):21-8 [12497202.001]
  • [Cites] Mol Cancer Ther. 2002 Dec;1(14):1273-81 [12516960.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):110-6 [12563310.001]
  • [Cites] J Pathol. 2003 May;200(1):59-64 [12692842.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4125-31 [14519635.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):1007-13 [14559983.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2461-8 [15059899.001]
  • [Cites] Mod Pathol. 2004 Jul;17(7):827-31 [15044924.001]
  • [Cites] Hum Pathol. 2004 Sep;35(9):1053-7 [15343505.001]
  • [Cites] Radiology. 1983 Feb;146(2):481-6 [6294737.001]
  • [Cites] J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S1-4 [11078319.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:851-76 [11264479.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):734-40 [12118111.001]
  • [Cites] Am J Surg. 1993 Mar;165(3):376-9 [8383473.001]
  • [Cites] Eur J Cancer. 1993;29A(9):1252-6 [8393684.001]
  • (PMID = 17158636.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Endothelin-1; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1972415
  •  go-up   go-down


84. Avoranta T, Sundström J, Korkeila E, Syrjänen K, Pyrhönen S, Laine J: The expression and distribution of group IIA phospholipase A2 in human colorectal tumours. Virchows Arch; 2010 Dec;457(6):659-67
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression and distribution of group IIA phospholipase A2 in human colorectal tumours.
  • The aim of this study was to examine the distribution and expression of IIA PLA2 protein in benign, premalignant and malignant colorectal tumours as well as in peritumoural mucosa.
  • A total of 79% of adenomas and 31% of carcinomas showed IIA PLA2-immunopositive tumour cells in IHC, and the expression was localised to epithelial cells with ISH.
  • The epithelial cells in the peritumoural mucosa showed immunopositivity for IIA PLA2 in 96% of cases, with considerably stronger intensity adjacent to carcinoma than in the more distal mucosa.
  • Moreover, IIA PLA2-immunopositive malignant epithelial cells were found in 44% of cases in the invasive front of carcinomas.
  • Our results suggest that the IIA PLA2 protein content is dramatically decreased in malignant colorectal tumours as compared with adenomas.
  • [MeSH-minor] Aged. Aged, 80 and over. Apoptosis. Biopsy. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Male. Middle Aged. Necrosis. RNA, Messenger / metabolism. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20938784.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.1.1.4 / Group II Phospholipases A2
  •  go-up   go-down


85. Kusafuka K, Ueno T, Kurihara K, Murata T, Yurikusa T, Henmi H, Akane M, Ota Y, Kameya T: Cystadenoma of the palate: immunohistochemistry of mucins. Pathol Int; 2008 Aug;58(8):524-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystadenoma is a relatively rare benign epithelial tumor of the salivary glands, and described herein is an additional case.
  • Histologically, the tumor was composed of bilayered columnar epithelium with cystic change and partial solid growth of glandular structures with clear cells.
  • The tumor cells had mild cellular atypia, but the tumor lacked papillary growth and a fibrous capsule.
  • Immunohistochemistry was positive for cytokeratins, epithelial membrane antigen, MUC1, MUC4 and MUC6, but negative for myoepithelial markers, MUC2, MUC5AC and MUC5B.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Humans. Immunohistochemistry. Male. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705774.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


86. Rosner IL, Ravindranath L, Furusato B, Chen Y, Gao C, Cullen J, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G: Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy. Urology; 2007 Dec;70(6):1225-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
  • Because AR mutations or amplification are rare in early stage CaP, we hypothesized that altered AR expression in prostate tumor cells may provide a prognostic indicator of disease progression.
  • METHODS: RNA from laser capture microdissected (LCM) tumor and benign epithelial cells from radical prostatectomy specimens of 115 hormone-naive patients were studied.
  • A ratio of the expression of AR gene, normalized to GAPDH gene expression in the same specimens, was compared in tumor and benign epithelial cells (tumor-to-benign ratio) and correlated with clinicopathologic features.
  • RESULTS: Paired t test analysis revealed a 62% lower AR expression in tumor tissue compared with benign tissue (P = 0.0005).
  • However, multivariate Cox proportional hazards regression analysis of time to PSA recurrence revealed that higher tumor cell associated AR expression (continuous, log-transformed), significantly increases odds of prostate-specific antigen (PSA) recurrence (P = 0.0139) when controlling for age at surgery, race, time from diagnosis to surgery, risk stratification, pathologic T stage, Gleason sum, and margin status.
  • CONCLUSIONS: Quantitative determination of AR gene expression levels in prostate epithelial cells may be useful for predicting PSA recurrence.


87. Obulareddy SJ, Xin J, Truskinovsky AM, Anderson JK, Franklin MJ, Dudek AZ: Metanephric adenoma of the kidney: an unusual diagnostic challenge. Rare Tumors; 2010;2(2):e38
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although metanephric adenoma (MA) is a rare, benign neoplasm of epithelial cells, it is often difficult to distinguish this entity from other malignant neoplasms preoperatively.
  • We report a case of a large renal mass for which preoperative diagnosis was indeterminate, with the differential diagnosis including Wilm's tumor, MA, and papillary renal cell carcinoma (PRCC).
  • Accurate postoperative differentiation of MA from PRCC is critical because adjuvant therapy is considered after surgical resection of PRCC tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139840.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994510
  • [Keywords] NOTNLM ; Wilm’s tumor / differential diagnosis. / metanephric adenoma / papillary renal cell carcinoma
  •  go-up   go-down


88. Guo RX, Qiao YH, Zhou Y, Li LX, Shi HR, Chen KS: Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol Int; 2008 Dec;58(12):749-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer.
  • AKT plays an important role in malignant behavior of tumors.
  • The purpose of the present study was to determine the expression of phosphorylated AKT (P-AKT) and nuclear factor-kappaB (NF-kappaB) p65 and their association with clinicopathological parameters and prognosis in epithelial ovarian tumor.
  • On immunohistochemistry 115 samples of ovarian tissue that included 68 specimens of epithelial ovarian cancer, 12 of borderline tumor, 24 of epithelial benign tumor and 11 of normal ovary, were evaluated.
  • The positive expression rate of P-AKT and NF-kappaB p65 were higher in epithelial ovarian cancer than in normal ovarian tissue (P<0.01).
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Phosphorylation. Prognosis. Survival Rate. Up-Regulation. Young Adult


89. Kamil ZS, Tong LC, Habeeb AA, Ghazarian D: Non-melanocytic mimics of melanoma: part I: intraepidermal mimics. J Clin Pathol; 2009 Feb;62(2):120-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Melanoma comprises a wide range of cytological and architectural features histopathologically and hence can mimic many benign and malignant lesions of epithelial, mesenchymal and hematopoietic cell lines of differentiation.
  • In this review, the different features of the benign, pre-malignant and malignant intraepidermal non-melanocytic tumours and tumour-like lesions that can closely mimic intraepidermal melanoma (melanoma in situ) are emphasised.
  • [MeSH-minor] Diagnosis, Differential. Humans. Keratosis / pathology. Precancerous Conditions / pathology. Skin Diseases / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18930985.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 40
  •  go-up   go-down


90. Wang Q, Zhang P, Zhang Q, Wang X, Li J, Ma C, Sun W, Zhang L: Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J; 2008 Apr;49(2):192-200
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of CD137 and CD137L expression in human primary tumor tissues.
  • AIM: To assess the expression of CD137 and CD137L in human primary tumor tissues and their potential role in tumor immunity.
  • METHODS: Expression of CD137 and CD137L was assessed by immunohistochemistry in frozen sections of 12 human normal tissues, 15 benign tumors of epithelial or mesenchymal origin (adenoma and leiomyoma), and 36 malignant tumors of epithelial origin (squamous cell carcinoma and adenocarcinoma).
  • The expression of CD137L on 9 human tumor cell lines (3 hepatocarcinoma, 2 lung carcinoma, 2 colon carcinoma, 1 lymphoma, and 1 leukemia) was detected by reverse transcription polymerase chain reaction.
  • To analyze the role of CD137L expressed on tumor cells, we co-cultured tumor cells expressing CD137L with activated T lymphocytes expressing CD137 or with Chinese hamster ovary cells expressing CD137 and then detected by ELISA the levels of cytokines (IL-8, IFN-gamma) secreted by tumor cells or activated T cells.
  • RESULTS: The expression of CD137 and CD137L was observed only in human benign (2/15, 3/15) or malignant tumors (15/36, 21/36), but not in normal tissues (0/12, 0/12).
  • CD137 was expressed on the vessel walls within tumor tissues, whereas CD137L was expressed on tumor cells.
  • The expression of CD137 and CD137L was more common in malignant tumors, especially in moderate or low-differentiated tumors.
  • Furthermore, CD137L expression found on tumor cell lines was functional because the ligation of CD137L on lung squamous carcinoma cells L78 with CD137 on T cells induced IFN-gamma production by T cells, and ligation of CD137L on hepatocarcinoma cells HepG2.2.15 with CD137 triggered tumor cells to produce IL-8.
  • CONCLUSION: CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors.
  • [MeSH-minor] Cell Line, Tumor. Disease Progression. Humans. Immunohistochemistry. Signal Transduction. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Immunol Ther Exp (Warsz). 1999;47(5):275-9 [10604232.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2903-10 [10946324.001]
  • [Cites] Am J Clin Pathol. 2001 Apr;115(4):543-9 [11293902.001]
  • [Cites] J Immunol. 2001 Aug 1;167(3):1313-24 [11466348.001]
  • [Cites] J Immunol. 2002 May 15;168(10):4897-906 [11994439.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3459-65 [12067989.001]
  • [Cites] Eur J Immunol. 2002 Dec;32(12):3617-27 [12516549.001]
  • [Cites] Cell Immunol. 2003 Nov;226(1):37-44 [14746806.001]
  • [Cites] Transpl Int. 2004 Aug;17(7):351-61 [15349720.001]
  • [Cites] Blood. 1995 Feb 15;85(4):1043-52 [7849293.001]
  • [Cites] J Immunol. 1995 Oct 1;155(7):3360-7 [7561030.001]
  • [Cites] J Immunol. 1998 Mar 1;160(5):2488-94 [9498794.001]
  • [Cites] J Exp Med. 1998 Jun 1;187(11):1849-62 [9607925.001]
  • [Cites] Semin Immunol. 1998 Dec;10(6):481-9 [9826581.001]
  • [Cites] J Leukoc Biol. 2005 Mar;77(3):281-6 [15618293.001]
  • [Cites] Annu Rev Immunol. 2005;23:23-68 [15771565.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):122-33 [15831231.001]
  • [Cites] J Immunother. 2005 Sep-Oct;28(5):449-60 [16113601.001]
  • [Cites] Hum Gene Ther. 2006 Aug;17(8):798-806 [16942440.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2758-67 [17460060.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4910-8 [17878391.001]
  • (PMID = 18461674.001).
  • [ISSN] 1332-8166
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / 4-1BB Ligand; 0 / Antigens, CD137
  • [Other-IDs] NLM/ PMC2359873
  •  go-up   go-down


91. Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, Chinnaiyan AM, Macoska JA: CXCL5 promotes prostate cancer progression. Neoplasia; 2008 Mar;10(3):244-54
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unlike many other chemokines, CXCL5 is secreted by both immune (neutrophil, monocyte, and macrophage) and nonimmune (epithelial, endothelial, and fibroblastic) cell types.
  • The current study was intended to determine which of these cell types express CXCL5 in normal and malignant human prostatic tissues, whether expression levels correlated with malignancy and whether CXCL5 stimulated biologic effects consistent with a benign or malignant prostate epithelial phenotype.
  • The results of these studies show that CXCL5 protein expression levels are concordant with prostate tumor progression, are highly associated with inflammatory infiltrate, and are frequently detected in the lumens of both benign and malignant prostate glands.
  • Exogenous administration of CXCL5 stimulates cellular proliferation and gene transcription in both nontransformed and transformed prostate epithelial cells and induces highly aggressive prostate cancer cells to invade through synthetic basement membrane in vitro.
  • These findings suggest that the inflammatory mediator, CXCL5, may play multiple roles in the etiology of both benign and malignant proliferative diseases in the prostate.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 2004 Oct 1;154(1):36-43 [15381370.001]
  • [Cites] J Cancer Res Clin Oncol. 2007 Nov;133(11):835-40 [17479287.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1809-18 [6831420.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):14-24 [7535634.001]
  • [Cites] J Leukoc Biol. 1997 Nov;62(5):604-11 [9365115.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2272-81 [9528798.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1503-12 [10329603.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1999 Jul-Aug;35(7):403-9 [10462204.001]
  • [Cites] Prostate. 1999 Oct 1;41(2):78-88 [10477904.001]
  • [Cites] Lab Invest. 2004 Dec;84(12):1666-76 [15467730.001]
  • [Cites] Arthritis Rheum. 2005 Mar;52(3):710-21 [15751074.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4117-27 [15930347.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1170-81 [15498784.001]
  • [Cites] J Immunol. 2005 Oct 15;175(8):5351-7 [16210641.001]
  • [Cites] Aging Cell. 2005 Dec;4(6):291-8 [16300481.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Feb;45(2):136-46 [16235240.001]
  • [Cites] BJU Int. 1999 Dec;84(9):976-81 [10571623.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1985-92 [10595928.001]
  • [Cites] Urology. 2000 Nov 1;56(5):828-32 [11068311.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1832-7 [11912162.001]
  • [Cites] J Urol. 2002 May;167(5):2267-70 [11956490.001]
  • [Cites] Tumour Biol. 2002 Mar-Apr;23(2):93-102 [12065847.001]
  • [Cites] J Biol Chem. 2003 Nov 21;278(47):47038-45 [12970366.001]
  • [Cites] Gene. 2004 Jan 7;324:1-14 [14693367.001]
  • [Cites] Fertil Steril. 2004 Feb;81(2):305-8 [14967364.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 30;320(3):656-63 [15240098.001]
  • [Cites] FASEB J. 2004 Aug;18(11):1240-2 [15180966.001]
  • [Cites] Genome Res. 2006 Feb;16(2):197-207 [16365378.001]
  • [Cites] Oral Oncol. 2006 Mar;42(3):240-56 [16266819.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4279-84 [16618752.001]
  • [Cites] Cancer Sci. 2006 Aug;97(8):697-702 [16800820.001]
  • [Cites] Prostate. 2006 Dec 1;66(16):1721-8 [16941672.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Oncogene. 2007 Mar 22;26(13):1971-82 [17043662.001]
  • [Cites] J Biol Chem. 2007 Sep 14;282(37):26767-74 [17631494.001]
  • [Cites] Invest Urol. 1979 Jul;17(1):16-23 [447482.001]
  • (PMID = 18320069.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA046592; United States / NIDDK NIH HHS / DK / P50 DK065313; United States / NCI NIH HHS / CA / 5 P30 CA46592; United States / NCI NIH HHS / CA / 5 P50 CA068568
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL5 protein, human; 0 / Chemokine CXCL5; 0 / EGR1 protein, human; 0 / Early Growth Response Protein 1; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC2262133
  •  go-up   go-down


92. Cardillo MR, Ippoliti F: Interleukin-6, interleukin-10 and heat shock protein-90 expression in renal epithelial neoplasias and surrounding normal-appearing renal parenchyma. Int J Immunopathol Pharmacol; 2007 Jan-Mar;20(1):37-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-6, interleukin-10 and heat shock protein-90 expression in renal epithelial neoplasias and surrounding normal-appearing renal parenchyma.
  • Cytokines, notably the interleukins IL-6 and IL-10, have an important role in the development and progression of renal-cell carcinomas, acting in the host-tumor interaction and in tumor bulk.
  • Heat shock proteins (HSP), in particular HSP-90, may have a regulatory role in cytokine biosynthesis and prognostic implication in some tumors.
  • IL-6, IL-10 and HSP-90 proteins were more strongly expressed in epithelium and stroma of the renal tumoral compartment than in adjacent normal peritumoral tissue.
  • The percentage of cells expressing IL-6, IL-10 and HSP-90 immunoreactivity was higher in benign epithelial tumors, than in normal peritumoral tissue, but lower than in renal-cell carcinomas.
  • Whereas HSP-90 immunoreactivity seemed higher in more aggressive histological phenotypes (collecting-duct carcinoma) of renal-cell carcinomas, IL-10 protein levels were higher in more advanced TNM stage (pT3) tumors.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17346426.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HSP90 Heat-Shock Proteins; 0 / Interleukin-6; 130068-27-8 / Interleukin-10
  •  go-up   go-down


93. Mirza S, Bradley PJ, Acharya A, Stacey M, Jones NS: Sinonasal inverted papillomas: recurrence, and synchronous and metachronous malignancy. J Laryngol Otol; 2007 Sep;121(9):857-64

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Inverted papillomas are relatively rare, benign epithelial tumours of the nasal cavity which generate considerable interest because they are locally aggressive, have a tendency to recur and are associated with malignancy.
  • [MeSH-major] Neoplasm Recurrence, Local / epidemiology. Papilloma, Inverted / epidemiology. Paranasal Sinus Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17319993.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 69
  •  go-up   go-down


94. Xu J, Zhang S, You C, Wang X, Zhou Q: Microvascular density and vascular endothelial growth factor have little correlation with prognosis of craniopharyngioma. Surg Neurol; 2006;66 Suppl 1:S30-4
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Craniopharyngioma is histologically a benign epithelial tumor located in the supersellar cistern that often presents aggressive growth and repeated recurrence.
  • METHODS: The cohorts consisted of 32 patients with AE and 31 patients with SP tumor.
  • CONCLUSIONS: Microvascular density and VEGF in craniopharyngioma tissue have no correlation with prognosis of the tumor, which may be explained by the minimal blood circulation in the craniopharyngioma.
  • Adamantine epithelioma showed more tendency to recur than SP.
  • [MeSH-major] Craniopharyngioma / blood supply. Craniopharyngioma / metabolism. Neoplasm Recurrence, Local / etiology. Pituitary Neoplasms / blood supply. Pituitary Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16904996.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


95. Zhao SJ, Liu JY, Ren FR, Feng YJ: [Expression of glucose transporter-1 and its correlation with basic fibroblast growth factor and proliferating cell nuclear antigen in epithelial ovarian neoplasm]. Zhonghua Fu Chan Ke Za Zhi; 2005 Apr;40(4):264-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of glucose transporter-1 and its correlation with basic fibroblast growth factor and proliferating cell nuclear antigen in epithelial ovarian neoplasm].
  • OBJECTIVE: To study the expression of glucose transporter-1 (GLUT1) and its correlation with basic fibroblast growth factor (bFGF) and proliferating cell nuclear antigen (PCNA) in epithelial ovarian neoplasm.
  • METHODS: Streptavidin-peroxidase complex technique was used to examine the expression of GLUT1, bFGF and PCNA protein in six cases of normal ovarian tissue, 20 cases of benign epithelial tumors, seven cases of borderline tumor and 44 cases of epithelial ovarian carcinoma.
  • RESULTS: In normal ovary and benign ovarian tumor, GLUT1 was not detected, but in borderline ovarian tumor and cancer, the positive expression ratio of GLUT1 was 6/7 and 91% (40/44), respectively.
  • The intensity of GLUT1 in ovarian epithelial neoplasm was significantly higher than in borderline tumors.
  • The staining intensity of GLUT1 was significantly correlated with the histological grade of the tumor (r(S) = 0.499, P = 0.001), and was positively correlated with the clinical stage, cancer invasion and lymph node metastasis.
  • bFGF positive rate in tumor was 57% (25/44).
  • CONCLUSIONS:. (1) The expression of GLUT1 may be closely related to malignant transformation of ovarian epithelial tumors.
  • Both of them play important roles in the carcinogenesis and progression of ovarian epithelial carcinoma.
  • [MeSH-major] Epithelium / metabolism. Fibroblast Growth Factor 2 / metabolism. Glucose Transporter Type 1 / genetics. Ovarian Neoplasms / genetics. Ovarian Neoplasms / metabolism. Proliferating Cell Nuclear Antigen / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15924676.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Proliferating Cell Nuclear Antigen; 0 / SLC2A1 protein, human; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


96. Tan TJ, Tan TY: CT features of parotid gland oncocytomas: a study of 10 cases and literature review. AJNR Am J Neuroradiol; 2010 Sep;31(8):1413-7
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oncocytomas of the salivary glands are rare benign epithelial tumors which occur most commonly in the parotid gland.
  • The CT features of parotid oncocytomas in the largest imaging series of this rare but important benign lesion include a well-defined enhancing tumor with a "deformable" appearance when large, and a non-enhancing curvilinear cleft or cystic component.
  • These CT findings are potentially helpful in distinguishing these benign lesions from other parotid tumors in clinical scenarios that preclude surgical resection or when biopsy results are non-diagnostic.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20395389.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


97. Schittenhelm J, Ebner FH, Harter P, Bornemann A: Symptomatic intraspinal oncocytic adrenocortical adenoma. Endocr Pathol; 2009;20(1):73-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most intraspinal neoplasms of epithelial origin are metastases from primary carcinomas.
  • Benign epithelial tumors are rarely found at this site.
  • We here present the case of a 44-year-old woman with a lesion in the cauda equina that fulfilled the radiologic criteria of schwannoma and caused clinical symptoms for 3 years.
  • The excised tumor was composed of nests of large polygonal cells with eosinophilic partial granular cytoplasm.
  • The tumor showed diffuse positivity for melan-A, synaptophysin, and alpha-inhibin.
  • Ultrastructural examination showed abundant mitochondria, suggesting an oncocytic tumor.
  • These extraadrenal tumors are thought to arise from heterotopic adrenocortical tissue in the spinal cavity.
  • Oncocytic tumors are rare neoplasms and they comprise non-functioning variants of adrenal cortical adenomas.
  • To date, only five such intraspinal tumors have been observed.
  • Immunohistochemistry excluded oncocytic paraganglioma, oncocytic meningioma, renal cell carcinoma, alveolar soft part sarcoma, and granular cell tumor.
  • A view of the literature of these rare but probably underdiagnosed intraspinal tumors is given.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19039533.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Uranues S, Alimoglu O, Todoric B, Toprak N, Auer T, Rondon L, Sauseng G, Pfeifer J: Laparoscopic resection of the pancreatic tail with splenic preservation. Am J Surg; 2006 Aug;192(2):257-61
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common indications are enucleation of endocrine-active tumors and distal resections for benign primary pancreatic lesions.
  • There were 4 cases of benign epithelial tumors of the pancreas and 1 case of a left-sided adrenal cyst, which pre- and intraoperatively gave the impression of a pancreatic cystadenoma.
  • No patient required blood transfusion, and there was only 1 postoperative fluid collection at the site of the tumor resection, which was drained percutaneously on the fourth postoperative day.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16860642.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Furusato B, Shaheduzzaman S, Petrovics G, Dobi A, Seifert M, Ravindranath L, Nau ME, Werner T, Vahey M, McLeod DG, Srivastava S, Sesterhenn IA: Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens. Prostate Cancer Prostatic Dis; 2008;11(2):194-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens.
  • Furthermore, to increase the sample quality, we utilized laser capture microdissection of prostate tumor and benign epithelial cells.
  • [MeSH-major] Adenocarcinoma / genetics. Epithelial Cells / metabolism. Gene Expression Profiling. Neoplasm Proteins / genetics. Prostate / metabolism. Prostatic Neoplasms / genetics. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Tissue Preservation / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17768422.001).
  • [ISSN] 1476-5608
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


100. Halbritter SA, Altermatt HJ, Caversaccio M, Bornstein MM: Apocrine papillary cystadenoma of a minor salivary gland on the lower lip: case presentation. Quintessence Int; 2009 Feb;40(2):167-9
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine papillary cystadenoma of a minor salivary gland on the lower lip: case presentation.
  • Cystadenomas are a rare, painless, and slow-growing benign epithelial tumor of the salivary gland.
  • This article describes the case of a papillary cystadenoma in the lower lip of a 46-year-old man.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169449.001).
  • [ISSN] 1936-7163
  • [Journal-full-title] Quintessence international (Berlin, Germany : 1985)
  • [ISO-abbreviation] Quintessence Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement